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ABSTRACT 
 
Salicylihalamide A, a potent cytotoxic natural product, was isolated by Boyd and 
co-workers in 1997 from a marine sponge Haliclona sp. collected from waters around 
Rottnest Island which is situated 18 km off the coast of southern Western Australia. This 
compound is characterized by a unique structure as well as by different biological activities 
with interesting mechanisms of action, displaying cytotoxicity at nanomolar levels against 
several human tumor cell lines. 
The majority of SAR studies have been conducted on salicylihalamide derivatives 
with modified enamide side chains as well as on the 12-membered ring and it has been 
shown that some small modification of the enamide moiety or of the macrolactone ring are 
tolerated without substantial loss of cytotoxic activity. For example, the semisynthetic 15-
aza-epothilone B was found to exhibit a better therapeutic range than epothilone B because 
of the stability of the macrolactam. 
This led us to our hypothesis that the modification of the 12-membered 
macrolactone in salicylihalamide A to a macrolactam would provide a more stable 
macrocyclic system and thus would be an interesting target for synthesis and biological 
evaluation.  
A key step in the synthesis of the new lactam analogue of salicylihalamide A was a 
photochemical acylation reaction. In order to prepare the desired E-lactam we have 
investigated the formation of the macrocyle using a RCM procedure. Conversion of 
macrolactam into the vinyl iodide followed by Cu catalysed cross coupling with the 2,4-
(Z,Z)-heptadienoic amide gave the 15-aza-salicylihalamide A analogue in good yield. 
Due to its promising bioactivity profile, the first total synthesis of the novel 
salicylihalamide A lactam analogue was accomplished in 17 linear steps from 2,6-
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dihydroxybenzoic acid with an overall yield of 0.70%. 
The new analogue was tested for cell growth inhibition against several leukemia cell lines. 
The results showed that the 15-aza-salicylihalamide A analogue exhibited antiproliferative 
effects at sub-micromolar concentrations.  
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Introduction Chapter 1
1.1 Introduction 
 
 The marine environment has proven to be a rich source of novel bioactive natural 
compounds with cytotoxic effects or specific effects on cellular targets. These natural 
products have demonstrated the invaluable role played in the drug discovery process 
related to all disease types and, in particular, in the areas of cancer and infectious diseases. 
They can be extremely potent in culture, with inhibitory concentrations generally in the 
nanomolar concentrations.1  
 Salicylihalamides A (1a) and B (1c) (Figure 1) are marine metabolites which are 
characterised by a unique structure as well as by different biological activities with 
interesting mechanisms of action. Both salicylihalamide A (1a) and B (1c) are members of 
a new family of cytotoxic natural products isolated from the sponge Haliclona sp. by Boyd 
and co-workers in 1997 and display cytotoxicity at nanomolar levels against several human 
tumor cell lines.2  
 
 
 
 
 
Figure 1.      Salicylihalamide A and B 
  
Structurally, these compounds feature a 12-membered macrolide ring that includes a 
salicylic acid residue with the macrolactone carrying a multiunsaturated side chain 
consisting of an unusual acyl enamine moiety and a (2Z,4Z)-heptadienamide system. 
Testing of salicylihalamide A (1a) in the NCI-60 cell line human tumour screen gave a 
 3 
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striking pattern of differential toxicity, which did not correlate with the profiles of any 
known antitumor compounds in the standard database. These results suggest that 
compound 1a has a novel mechanism-of-action and further biological evaluation revealed 
that compound 1a was the first of a new class of mammalian specific vacuolar-type (H+)-
ATPase inhibitor. 
 
1.2 Biological significance of Vacuolar (H+) – ATPases 
 
 Eukaryotic cells contain single membrane-bounded organelles, such as Golgi 
apparatus, coated vesicles, vacuoles of plants and fungi, endosomes, lysosomes, 
endoplasmic reticulum, secretory granules and synaptic vesicles.3 Their lumina are acidic, 
with pH from 4.5 to 6.5. Environmental pH regulation is essential to the function of many 
biological systems4 and each organelle maintains a characteristic internal pH close to the 
physiological range, which is crucial to normal cell function due to the narrow pH optima 
of many cellular processes.5 A defect in organellar acidification in mammalian cells is 
correlated with an increasing number of diseases such as male infertility,6 renal acidosis,  
tumor metastasis and osteopetrosis (thickening of the bones and skull and skeletal defects 
due to the inability of osteoclasts to degrade bone). The acidic environment in organelles is 
necessary to promote the activity of hydrolases responsible for degradation of proteins and 
other macromolecules and the release of ligands from receptors.7 It is well established8 that 
the acidic pH in organelles is generated by the action of a vacuolar-type H+-ATPase (V-
ATPase), a primary proton pump that plays a key role in the proper functioning of internal 
organelles such as vacuoles, endosomes, lysosomes, synaptic vesicles, secretory granules, 
and the Golgi apparatus as well as on plasma membranes of diverse organelles. The core 
function of protein complex V-ATPase is to pump protons out of the cytoplasm into the 
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organelle or the extracellular space9 using the chemical energy released by adenosine 
triphosphate (ATP) hydrolysis. This multi-subunit electrogenic proton pump (V-ATPase) 
plays crucial roles in sperm storage and maturation (maintaining sperm in an immotile 
state in the epididymis and vas deferens),10 body acid-base regulation (renal proximal 
tubule and collecting duct intercalated cells),11,12 inhibition of bone remodeling 
(osteoclasts),12,13 pH homeostasis, coupled transport and tumor metastasis.13  
Loss of V-ATPase activity due to protein mutations in particular cell types has been 
implicated in diverse pathophysiological states such as kidney and bone disease 
(inadequate bone resorption caused by osteoclast dysfunction),14 cutis laxa syndrome 
(wrinkly skin syndrome -  loose and redundant skin folds and  decreased elasticity of the 
skin)14 and sensorineural deafness.15 Thus V-ATPase functions in a very broad array of 
physiological processes, performing diverse biological activities within cells. 
 
1.3 Structure of the V-ATPases and relationship to F-ATPases 
 
 V-ATPases are large (900-kDa) multisubunit complex enzymes containing at least 
13 distinct subunits, some of which occur in mammalian tissues as multiple isoforms.16 
They are comprised of two domains, a membrane-embedded V0 domain and an extra 
membranal soluble V1 domain. The energy gained from ATP-hydrolysis by the V1 domain 
is used by the V0 domain to pump protons from the cytosol to the non-cytosolic space. The 
soluble V1 domain is a complex of 640 kDa including at least eight different subunits (A–
H) and is responsible for ATP hydrolysis. The A and B subunits serve as the ATP binding 
sites, with the catalytic site located on the A subunit.17 The membrane-embedded V0 a 260 
kDa subcomplex, includes subunits a, c, c′, c′′, d, and e and is responsible for proton 
translocation across the membrane in which it is anchored. The a subunit of the proton 
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pump is considered essential for coupling of ATP hydrolysis (V1) and proton transport 
(V0).17 Subunit c seems to significantly influence the proliferation and metastasis of tumor 
cells18 and inhibition of this subunit resulted in the suppression of growth and metastasis19 
which is overexpressed in most human cancers, including liver carcinoma.20 
  
Figure 2.      Comparison of ATPases21 
 
 There are three known types of ATPases – P-ATPases, F-ATPases, and V- 
ATPases (Figure 2). The P-type ATPases are membrane proteins responsible for the 
transport of a variety of cations across cell membranes using ATP hydrolysis for energy.22 
There are many different classes of P-ATPases, each of which transports a specific type of 
ion: Na+, K+, Mg2+, Ca2+, Ag+ and Ag2+, Zn2+, Co2+, Pb2+, Ni2+, Cd2+, Cu+ and Cu2+. 
V-ATPases have similar structure and mechanism of action as F-ATPase.23 In contrast to 
F-ATPases, whose primary function is to synthesize ATP from ADP, V-ATPases uses the 
energy derived from ATP hydrolysis to transport protons across the lysosomal 
membrane.24 
  
have been recognized by Nobel prizes to Peter Mitchell in
1978 and to John E. Walker, Paul D. Boyer, and Jens Skou in
1997. The part that is not universally accepted is the postulate
that animal cell plasma membranes are energized by H!
V-ATPases. Instead, animal cell membranes are said to be
energized by Na!/K! P-ATPases, with H! V-ATPase energi-
zation being restricted to certain ‘‘specialized’’ animal cell
membranes. We will show that the broader view is correct—
animal plasma membranes, especially apical membranes of
epithelial cells, are frequently energized by H! V-ATPases.
Three classes of proton-motive ATPases
H! F-ATP synthases have a molecular mass of !400 kDa
and consist of at least nine subunits arranged in a catalytic/
regulatory F1 sector and an H!-translocating Fo sector (Fig.
1C). The F1 subunit stoichiometry is "3#3$%&; the Fo stoichiom-
etry is abc12d in mitochondria and is similar in chloroplasts
and bacterial plasma membranes. The structure of an F1
subcomplex has been determined at the 2.8 A˚ level,(5) and
has features that support Boyer’s(6) conformation coupling
(‘‘rotatory $’’-subunit) mechanism for ATP synthesis. F-ATP
synthase activity is specifically inhibited by submillimolar
concentrations of azide. In some bacteria the enzyme uses
Na!, rather than H!, and hence is a Na! F-ATP synthase.
Like their sister F-ATPases, V-ATPases are multi-subunit,
heteromeric proteins, but they are larger, having a molecular
mass of !750 kDa (Fig. 1D). At least 13 genes encode the
different V-ATPase subunits in the most elaborately explored
case, the yeast Saccharomyces cerevisiae,(7–9) but the total
number of subunits may differ from case to case, probably
due to specific regulatory constraints. Also like their sister
F-ATPases, V-ATPases consist of a membrane-spanning,
proton-conducting complex and a peripheral, catalytic com-
plex. The peripheral complex, designated V1 by analogy with
the peripheral F1 complex of F-ATPases, consists of at least
seven subunits with a total molecular mass of !550 kDa(10);
the membrane-located Vo complex consists of three to four
subunits with a total mass of !250 kDa.(9) By analogy with
F-ATPases, V-ATPases are thought to employ a rotatory
mechanism of action but their moving subunits have yet to be
identified. V-ATPase activity is specifically inhibited by submi-
Figure 1. Comparison of ion-motive
ATPases: F-ATPase (coupling Factor), V-
ATPase (Vacuole), and P-ATPase (Phosphory-
lated intermediate). A: Mitochondrion—H!s
from electron transport pass through the F-
ATP synthase drivingATP synthesis. B:Model
cell—H! V-ATPase with Cl' channel acidifies
vacuole; apical H! V-ATPase or K!/H! P-
ATPase acidify lumen; basolateral Na!/K!
P-ATPase keeps cell [K!] high and cell [Na!]
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subunits #/" (red), connecting subunits $, %,
and & (pink) make up the F1 (peripheral)
domain; H! channel-forming subunit c along
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forming subunit M17, alongwith subunitsM9.7,
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have been recognized by Nobel prizes to Peter Mitchell in
1978 and to John E. Walker, Paul D. Boyer, and Jens Skou in
1997. The part that is not universally accepted is the postulate
that animal cell plasma membranes are energized by H!
V-ATPas s. Instead, animal cell membranes are said to be
energized by Na!/K! P-ATPases, with H! V-ATPase e ergi-
zation being rest icted to cert in ‘‘specialized’’ imal cell
membranes. We will show that the broader view is correct—
animal plasma membranes, especially apical membranes of
epithelial cells, are frequently energized by H! V-ATPases.
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H! F-ATP synthases have a molecular mass of !400 kDa
and consist of at least nine subunits arranged in a catalytic/
regulatory F1 sector and an H!-translocating Fo sector (Fig.
1C). The F1 subunit stoichiometry is "3#3$%&; the Fo stoichiom-
etry is abc12d in mitochondria and is similar in chloroplasts
and bacterial plas a membranes. Th structure of an F1
subcomplex has been determined at the 2.8 A˚ level,(5) and
has features that support Boyer’s(6) conformation coupling
(‘‘rotatory $’’-subunit) mechanism for ATP synthesis. F-ATP
synthase activity is specifically inhibited by submillimolar
concentrations of azide. In some bacteria the enzyme uses
Na!, rather than H!, and hence is a Na! F-ATP synthase.
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heteromeric proteins, but they are larger, having a molecular
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1.4     Role of V-ATPases inhibitors in cancer 
 
 Tumor cells in vivo often exist in a poor oxygenated region with a lower 
extracellular pH than that of surrounding normal tissues (pH 6.9-7.1), the acidic 
environment contributing to tissue damage, metastatic progression as well as activation of 
destructive enzymes.25 
The majority of tumor cells demonstrate substantially increased glucose uptake 
compared with normal tissue, converting glucose to ATP even in the presence of abundant 
oxygen, resulting in tumor cell acid production, which contributes, to the proliferation and 
invasion of cancer cells during the process of tumorigenesis and metastasis.26 In solid 
tumors, both intracellular and extracellular pH differ, thus tumor cells express various pH 
regulators to avoid apoptosis. However, cancer cells usually have neutral to alkaline 
cytosolic pH in the acidic extracellular microenvironment.27 
Recently, much attention has been paid to the roles that the highly active V-
ATPase plays in the pH regulation in tumor cells.28 V-ATPases located in the membranes 
of vacuolar systems of animal cells act as important proton transporters that regulate the 
cytosolic pH maintaining an alkaline intracellular environment favorable for growth, 
whereas the V- ATPases present in the plasma membrane of tumor and endothelial cells 
are involved in extracellular pH regulation.29 
 
1.5     V-ATPase inhibitors 
 
 In general, intracellular pH is similar in both solid tumor and normal tissues while 
extracellular pH is higher in normal tissue and lower in solid tumors, scientific evidence 
suggesting that the acidic tumor microenvironment is key to managing cancer development 
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and metastasis. As a consequence, these findings offer a possibility to develop novel 
compounds as agents that specifically target the mechanism(s) responsible for the acidic 
pH of tumors. Among the key regulators of the tumor acidic microenvironment, V-
ATPases play an important role because they can be inhibited by proton pump inhibitors.30 
Attempts to develop V-ATPase-targeted drugs have focused on the naturally occurring 
macrolide antibiotics concanamycins and bafilomycins (Figure 3). 
 
 
 
 
 
 
 
 
 
 
Figure 3.      Bafilomycin A1 and Concanamycin A 
 
This class of antibiotics has no effect on F-ATPases (which are structurally homologous to 
the V-ATPase) whereas some P-type ATPases are inhibited in the micromolar and V-
ATPases in the nanomolar concentration range.31 Concanamycins (an 18-membered 
plecomacrolides) are better and more specific inhibitors of V-ATPases than the 
bafilomycins with bafilomycin A1, (a 16-membered macrolactone) inhibiting bone 
resorption both in vitro32 and in vivo33. However, bafilomycin A1 cannot be administrated 
even in animal experiments, because it inhibits all the essential V-ATPases leading to 
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systemic alteration of cellular physiology and severe toxic effects.34 
 Another class of natural products that selectively inhibit V-ATPase activity in vitro 
is chondropsins that display potent cytotoxicity and produce a characteristic pattern of 
differential activity in the NCI 60-cell line antitumor screen.35 This class of macrolides has 
no inhibitory activity on F- and P-type ATPases enzyme and shows a high COMPARE 
correlation coefficient with the bafilomycin and concanamycin.36  
 Since the discovery of the salicylihalamides, the isolation of other natural products 
with the common characteristics of this new benzolactone enamide class has been reported. 
This family includes the apicularens with an identical enamide side chain37 and the 
lobatamides, oximidines I and II, CJ-12,950, and CJ-13,357 each with the highly 
unsaturated enamide side chain terminating in an O-methyl oxime as illustrated in Figure 
4.38 These natural compounds possess common structural features – a 12 or 15 – membered 
ring macrolactone and an α,β-unsaturated enamide side chain - and are the only known 
potent inhibitors that show a clear preference for inhibition of mammalian vacuolar 
ATPase activity and is ineffective toward V-ATPase from yeast and fungi in contrast to 
bafilomycins or concanamycins. They were shown to inhibit human kidney (IC50 0.58 
nM),39 liver (IC50 0.62 nM)40,41 and human osteoclast (IC50 0.40 nM)42,43 V-ATPase in 
membrane preparations at low nanomolar concentrations, but were inactive against V- 
ATPases of fungi (IC50  > 10,000 nM).44 In biological testing, these benzolactone enamides 
showed potent cytotoxic activity when tested in vitro for their ability to inhibit growth of 
60 human cancer cell lines from different organs of origin.  Studies of structure-activity 
relationships (SAR) of the salicylihalamide A and chemical analogues have helped to 
identify the minimal structural requirements for inhibition of V-APases.  
Since V-ATPases play crucial roles for many cellular processes, salicylihalamide is 
expected to be a promising anticancer drug candidate. 
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Figure 4.    Salicylihalamides and structurally related benzolactone acylenamine 
natural products. 
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1.6 Total synthesis of salicylihalamides 
 
 Immediately after their isolation and structural elucidation, the salicylihalamides 
have received considerable attention from various chemical synthesis research groups, due 
to their novel structural features and outstanding biological activity. 
The novel class of natural products known as the benzolactone enamide has a salicylic acid 
moiety, a macrolactone and an unusual highly unsaturated enamide side chain. Given the 
sensitive nature of the enamide side chain of this macrolide, the installation of this chain 
moiety has been done at a late stage in the synthesis. The 12-membered macrolactone can 
either be secured by ring closing metathesis or by intramolecular cross coupling reactions. 
The general route for the Mitsunobu esterification/ring closing metathesis strategy 
followed by the enamide side-chain installation45 is shown in Scheme 1. 
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Scheme 1. General route for the salicylihalamide syntheses (Mitsunobu 
esterification/ring closing metathesis/enamide side-chain installation) 
 
 
1.6.1.  Synthetic strategies for the salicylate precursors 
 
 De Brabander and co-workers commenced the construction of the macrolactone 
core of the salicylhalamides 1 (Scheme 2) from commercially available 2,6-
side chain 
insta lat
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dihydroxybenzoic acid 2.46 Treatment of the corresponding acid with acetone produced an 
isopropylidene intermediate, which was converted to acetonide triflate 3. The allyl 
substituent introduced by a Stille coupling of 3 with allylstannane, was followed by a 
Grignard addition to give allyl ester 4. Subsequent methylation and deprotection of the 
allyl group provided the allyl-anisic acid 5. 
 Labrecque et al. used the most direct route to prepare the same 6-allyl-2-
methoxybenzoic acid 5 by allylation of lithium o-anisate starting from the known o-anisic 
acid 6.47 Although the yields in this reaction are poor (18-48%), this method gives a quick 
access to the salicylate precursor. 
 According to Fürstner’s procedure,48 triflate 3 was converted to salicylic acid 
derivative 8 via allylation in high yield by a modified Suzuki-type reaction, followed by 
the cleavage of the isopropylidene group of 7.   
 Snider and Song introduced the allyl substituent by a Stille coupling reaction.49 
Reaction of 3 with allyltributyltin using Pd2(dba)3 and TFP followed by hydrolysis of the 
acetonide under basic conditions afforded 8 in a very good yield.  
 Smith and Zheng adopted a different strategy to obtain the same salicylate 
precursor, starting from the known amide 9.50 Using a conventional procedure involving 
the use of iodine in aqueous tetrahydrofuran mixture, the amide 9 was converted to an 
iodolactone 10, which was then treated with zinc in acetic acid to provide the allyl-anisic 
acid 5. 
 Maier et al. employed 5 as the starting material, which was converted to vinyl 
iodide 11 by formation of the aldehyde intermediate followed by Takai iodo-olefination.51  
 According to Rizzacasa’s procedure, 6-methyl salicylic acid 12 was converted to 
bromoacetonide 13 via acetonide formation followed by radical bromination, in order to 
construct the macrolaclacton core through a Stille coupling reaction.52 
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Scheme 2.     Synthetic strategies for the salicylate precursors 
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1.6.2.  Synthetic strategies for the alcohol precursors 
 
 De Brabander and co-workers46 initiated their synthesis of the Mitsunobu coupling 
precursor with the enantioselective allylation of the aldehyde 14 followed by the silylation 
and oxidative double-bond cleavage of 15 to afford aldehyde 16 (Scheme 3). To set the 
absolute stereochemistry at C15, this aldehyde was treated with (Z)-O-titanium enolate 
derived from 17 producing one diastereomeric aldol product 18. Alcohol protection of 18, 
followed by tosylate formation, reduction and desilylation afforded the alcohol 19.  
 
 
 
 
 
 
 
 
                                                                          
                                                                                X* = boranesultam 
 
 
 
Scheme 3.  Synthesis of the diastereomerically pure alcohol precursor 19 (De 
Brabander et al.)46 
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 Rizzacasa et al.52 developed a stereocontrolled construction of the vinyl stannane 
26 starting with the known optically pure acetal 20, which was then subjected to 
ozonolysis/reductive workup to afford the alcohol 21. Subsequent tosylation, lithium 
acetylide displacement, and DIBAL reduction of the acetal functionality, furnished the 
alcohol 23 (Scheme 4). Oxidation of the resultant alcohol with Dess-Martin periodinane 
and addition of allylmagnesium bromide afforded alcohol 25, which was separated from its 
diastereomeric contaminant via flash chromatography. The alcohol 24 could be converted 
to 25 by Mitsunobu inversion. The synthesis of 26 was completed by regioselective 
palladium-catalyzed hydrostannylation of terminal alkyne.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.     Synthesis of the diastereomerically pure alcohol precursor 26 (Rizzacasa 
et al.)52 
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 Fürstner and co-workers synthesized the alcohol precursor 35 as outlined in 
Scheme 5.48 After prenylation of Oppolzer’s bornanesultam 27 the desired compound 28 
was prepared with excellent diastereoselectivity and useful yield (79%). Saponification of 
28 with aqueous LiOH in THF, converting the resulting acid 29 to acid chloride 30 
followed by chain extension provided ß–exo ester 31. Chemo- and stereoselective 
hydrogenation of this ester gave the corresponding secondary alcohol 32, which was 
protected by a MOM group preparing the conditions for the construction of the chiral 
center at C15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5.     Synthesis of the diastereomerically pure alcohol precursor 35 (Fürstner et 
al.)48 
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 Smith and Zheng50 prepared the requisite alcohol precursor 41 by the route 
depicted in Scheme 6. Roush crotylboration coupling of aldehyde 36 and allyl boronate 37 
proceeded with excellent diastereoselectivity to give alcohol 38 in 88% yield and 90% 
diastereoselectivity. Protection of the secondary alcohol 38 as the t-butyldimethylsilyl 
ether, followed by hydroboration, Swern oxidation and Wittig methylenation led to alkene 
39 which was deprotected with aqueous trifluoroacetic acid to give the intermediate diol 
that was converted to the epoxide 40. Finally, treatment of the epoxide with vinyl Grignard 
in catalytic conditions gave the targeted intermediate 41 in 76% yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6.     Synthesis of the diastereomerically pure alcohol precursor 41 (Smith et 
al.)50 
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 Labrecque et al. 47 described the use of the known epoxide 42 for the preparation of 
Mitsunobu coupling precursor by the route presented in Scheme 7. The known epoxide was 
converted to the protected 1,3-diol 43 via sequential reduction and in situ protection with 
p-anisaldehyde. Cleavage of the O-protecting groups in the adduct by DIBAL-H followed 
by Dess–Martin oxidation and Roush crotylation afforded 44. This secondary alcohol was 
then submitted to silylation and hydroboration, which gave alcohol 45 in good overall 
yield. Dess–Martin oxidation followed by Wittig homologation and PMB deprotection 
with DDQ gave the desired alcohol 46. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7.     Synthesis of the diastereomerically pure alcohol precursor 46 (Labrecque 
et al.)47 
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The Snider and Song49 stereocontrolled synthesis of pure alcohol 53 is outlined in 
Scheme 8. The synthesis of building block 53 commenced with the LiBH4 reduction of the 
amide 47 followed by the Swern oxidation to provide aldehyde 48. This aldehyde was then 
subjected to asymmetric Carreira aldol condensation with 49, which gave an inseparable 
4.2:1 mixture of 50. Treatment of the alcohol 50 gave ß-keto ester 51, which was reduced 
to the syn alcohol and cyclized to the hydroxylactone 52.  
NaBH4 reduction to the lactol followed by the methyl acetal protection afforded cyclic 
ester 53 in an overall yield of 83%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8.     Synthesis of the diastereomerically pure alcohol precursor 52 (Snider and 
Song) 49 
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 Maier et al. have used as starting material aldehyde 55 and obtained the 
enantiomerically pure alcohol 61 in good yield  (Scheme 9).51 The aldehyde 55 was 
subjected to Duthaler aldol reaction with tert-butyl acetate to give 3-hydroxy ester 56 in 
83% ee. Protection of the resulting secondary hydroxyl group as the TIPS ether, followed 
by DIBALH reduction gave aldehyde 57, which was subjected to an Evans aldol reaction 
with 58 to afford 59 in quite good yield. Completion of alcohol 61 entailed formation of 
the MOM-ether, reductive removal of the chiral auxiliary with NaBH4, elimination in the 
presence of NaI and DBU, silyl deprotection and inversion of the alcohol 60.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 9.     Synthesis of the diastereomerically pure alcohol precursor 61 (Maier et 
al.)51 
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 Georg et al53 reported the synthesis of 66 in a nine step procedure, beginning with 
the known alcohol 63, which was prepared in five straightforward steps from diacetone-D- 
glucose 62 as a source for the three chiral centres of the molecule (chiral pool approach) 
(Scheme 10). Conversion of the alcohol 63 to the corresponding triflate followed by 
displacement with a higher order allylcyanocuprate provided alcohol 65. The acetonide 
function was cleaved with acetic acid and the resulting anomeric hydroxy group selectively 
oxidized to generate lactone 66. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10.     Synthesis of the diastereomerically pure alcohol precursor 66 (Georg et 
al.)53 
 
 Georg and co-workers on the basis of a similar strategy employed for compound 
66, performed the synthesis of the other diastereomer 71 adopting the chiral pool strategy 
toward the synthesis of the (-)-salicylihalamides (Scheme 11).54 Conversion of the 
hydroxyl group of 67 to the corresponding bromide 68 followed by the allylation set the 
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absolute stereochemistry at C12. Acidic hydrolysis of the acetonide moiety in 69 gave 70, 
and subsequently the lactol was oxidized selectively to lactone 71. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 11.     Synthesis of the diastereomerically pure alcohol precursor 71 (Georg et 
al.)54 
  
 Hanson and co-workers55, 56 have utilized temporary tethers in a recent tactic to join 
complex synthetic building blocks in moderate to good yield preparing the Mitsunobu 
coupling precursor 81 by the route outlined in Scheme 12. 
Construction of alcohol 81 began with the union of the 1,3-anti-Diol 72 and phosphoryl 
trichloride using the protocol of Rychnovsky and co-workers,57 to give the coupling 
product phosphoryl monochloride 73 in 90% yield. Formation of phosphate triester triene 
74 was next readily achieved, in one step, by addition of lithium allyloxide into 73, 
followed by ring-closing metathesis (RCM) to provide phosphate 75 in good yield.  
Alcohol 76, secured via a chemoselective hydroboration followed by oxidation, was 
elaborated to homologated phosphate ester 78 by PMB protection, diastereoselective 
cuprate addition and methylation. Completion of 81, the alcohol coupling partner, was 
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 achieved in six steps. First, phosphate 78 was converted via a three-step sequence to the 
corresponding diol 79, and then selectively protected as a TIPS-ether followed by MOM 
protection to furnished the fully protected triol 80. Desilylation of the resultant triol then 
furnished the alcohol 81 in 95% yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 12. Synthesis of the diastereomerically pure alcohol precursor 81 (Hanson et 
al.)55,56 
 
 
A comparison of the overall yields for the synthesis of the alcohol precursors discussed 
above is shown in Table 6 (Appendix C, page 167). 
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1.6.3  Methodology related to macrolactone ring formation 
 
 The first total stereoselective synthesis of salicylihalamides A was reported by De 
Brabander and co-workers (Scheme 13).46 The synthesis commenced with allylation of 
aldehyde 82 that provided the absolute stereochemistry at C15 for the known homoallyl 
alcohol 83. The other two chiral C12 and C13 centers were set by o diastereoselective 
aldol reaction on aldehyde 84. Condensation of allysalicylic acid 85 with 
diastereomerically alchhol 86 under Mitsunobu conditions followed by RCM produced 
macrolactone 87. To complete the total synthesis of 1a, the next step was the introduction 
of the acylated side-chain via an acyl azide formation and Curtius rearrangement followed 
by the addition of a nucleophile. 
 
 
 
 
 
Scheme 13.     De Brabander and co-workers synthesis of the ring-closing metathesis 
precursor of  (-) salicylihalamide A 
  
 The route developed by Fürstner and co-workers48 to the total synthesis of (-) 
Salicylihalamide A began with the construction of the stereocenter at C12 by prenylation 
of Oppolzer’s boranesultam 88 (Scheme 14). Stereoselective hydrogenation of ester 89 
creates the C13 chiral center while the remaining stereocenter at C15 is introduced by the 
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reduction of β-oxo ester 90, using the same catalyst but under slightly modified conditions. 
The macrocyclic core was built by ring-closing metathesis of the diene derived from 
compound 91 and alcohol 92 by Mitsunobu macrolactonization. A Cu-cross coupling 
process installed the amide 93. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 14.   Fürstner and co-workers synthesis of the ring-closing metathesis 
precursor of   (-) Salicylihalamide A 
 
 Smith and co-workers also completed the total synthesis of (-)-salicylihalamide A 
(Scheme 15).50 The formation of the required 12-membered lactone was achieved by 
means of Mitsunobu esterification followed by ring-closing metathesis of diene 94, which 
was assembled by coupling the two advanced fragments 5 and 41. Fragment 5 has been 
synthesized from the amide 9 (Scheme 2), while fragment 41 from the known aldehyde 36. 
The labile enamide bond was installed via N-acylation of the enecarbamate 96 with acid 
chloride 95. 
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Scheme 15. Smith and co-workers synthesis of the ring-closing metathesis precursor 
of  (-) salicylihalamide A 
  
 Snider and Song49 prepared the diene 97 via Mitsunobu coupling protocol of acid 8 
and cyclic ether 53 (Scheme 16). What is important to note is that the RCM of 96 did not 
proceed, “presumably because the diequatorial substituents on the tetrahydropyran ring 
kept the alkenes too far apart.”49 Hydrolysis of 96 in aqueous acetic acid and alkene 
homologation of the resulting lactol followed by TBS protection gave diene precursor 98, 
which was subjected to ring-closing metathesis to afford the macrolactone core. 
Completion of the (-)-salicylihalamide A was then achieved in eight steps. 
  
 
 
 
 
 
 
 
Scheme 16.   Snider and co-workers synthesis of the ring-closing metathesis precursor 
of  (-) salicylihalamide A 
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 In the Labrecque et al. 47 synthesis of (+)-salicylihalamides A (1a) and B (1b) 
outlined in Scheme 17, the diene 99 was constructed from Mitsunobu coupling of acid 5 
and alcohol 46, which upon ring-closing metathesis gave the macrolactone core 100. This 
benzolactone was converted to an aldehyde that was condensed with amide 101 to afford 
N,N’-bis-acylated aminal 102. By adopting the same synthetic sequence Labrecque’s group 
synthesized (-) salicylihalamides A and B using the enantiomer of 46.  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 17.     Labrecque and co-workers synthesis of the ring-closing metathesis 
precursor of  (-) salicylihalamide A 
 
 Georg et al. 54 used the RCM reaction technique to synthesize the macrocyclic core 
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Grubbs catalyst. Consequently the lactone was reduced to lactol 104 using DIBAL-H 
followed by a Wittig reaction with stabilized ylide 105 to afford acryl nitrile 106. The right 
chirality at C13 was achieved by a Mitsunobu esterification with p-nitrobenzoic acid, and 
the resulting acryl nitrile was subjected to a RCM reaction that provided macrocycle 107. 
Cleavage of the phenolic methyl ether followed by removal of Z-isomer and hydrolysis of 
the PNB group furnished the macrocyclic core structure 108. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 18.     Georg and co-workers synthesis of the ring-closing metathesis 
precursor of  (-) salicylihalamide A 
 
 Rizzacasa and co-workers have used a totally different strategy for the creation of 
the unsaturated benzolactone core of the salicylihalamides A and B (Scheme 19).52 Their 
approach relied on a Stille cross-coupling reaction between vinyl stannane 26 and 
bromoacetonide 13 to afford alkene 109 in good yield. Macrolactonization of the latter 
compound (NaH, THF) led to the intermediate macrolactone, from which the PMB group 
was removed (DDQ) followed by the TBS reprotection and cross metathesis (Grubbs’ 
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second generation catalyst) with acrylic acid to afford α,β–unsaturated acid 110. The latter 
intermediate had been used for De Brabander’s and Smith’s syntheses thereby completing 
the formal total synthesis of salicylihalamides A and B. 
 
 
 
 
 
 
 
 
 
Scheme 19.     Rizzacasa and co-workers synthesis of the ring-closing metathesis 
precursor of  (-) salicylihalamide A 
 
 Maier and co-workers58 achieved the total synthesis of salicylihalamides A and B, 
by preparing benzolactone 114 either by Suzuki cross-coupling/intramolecular Mitsunobu 
strategy or by the intermolecular Mitsunobu/ring closing metathesis strategy. While the 
ring-closing metathesis approach requires eight steps (22.8% overall yield), the Suzuki 
coupling/macrolactonization strategy requires nine steps but the overall yield (26.6%) is 
slightly higher. As illustrated in Scheme 20, the synthesis of 114 commenced with the 
hydroboration of alkene 111 followed by a Suzuki cross-coupling reaction with vinyl 
iodide 11 which gave the trans-alkene 112. Removal of the silyl ether group followed by 
the cleavage of the methyl ester moiety afforded the seco acid 113, which was converted to 
macrolactone 114 by a Mitsunobu reaction. After conversion of the latter compound to 
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aldehyde 115 over four steps, the amide 101 was introduced through hemiaminal formation 
and formal elimination of water. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 20.     Maier and co-workers synthesis of the ring-closing metathesis 
precursor of  (-) salicylihalamide A 
 
 The convergent strategy Hanson et al.55 implemented toward the synthesis of the 
salicylihalamides A and B is based on the construction of the macrolactone core (Scheme 
21). The synthesis of the latter stared with alcohol 81, which was obtained in 11 steps from 
the bicycle (R,R,Rp)-75. Addition of benzodioxinone 7 to alcohol 81 in the presence of 
NaH provided the functionalized aromatic alcohol 116, which was subsequently 
methylated to provide the RCM precursor 117 in 90% yield. Ring closing metathesis of 
diene 117 with second-generation Grubbs catalyst provided the salicylihalamides 
macrolide 118 in an E/Z ratio of 10:1. 
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Scheme 21.     Hanson and co-workers synthesis of the ring-closing metathesis 
precursor of salicylihalamide A and B 
 
 
1.6.4. Methodology related to installation of enamide side chain 
 
 In the total synthesis of (-) salicylihalamides A (1a), completed by Snider and co-
workers,49 the dienyl enamide was incorporated through the addition of hexadienyllithium 
cuprate 112 (prepared in situ from ethyllithium, copper bromide dimethyl sulfide complex 
and acetylene) to a solution of isocyanate 113 (derived from the corresponding (E)- α,β-
unsaturated carboxylic acid by acyl azide formation followed by Curtius rearrangement). 
The desired compound 114 was obtained in 43% yield together with two other byproducts 
(Scheme 22). 
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Scheme 22.      Snider’s synthesis of model enamide side chain 11449 
 
 Smith and co-workers50 developed a similar but more efficient system for the 
incorporation of the salicylihalmide side chain using the electrophile 115 instead of the 
nucleophilic hexadienyl intermediate 112 by trapping the latter with carbon dioxide to 
furnish 2,4-(Z,Z)-hexadienyl acid 115 (Scheme 23). N-acylation of sodium salt of 117 
(obtained by Curtius rearrangement and trapping of the resulting isocyanate with 
trimethylsilylethanol) with dienyl acyl chloride 116 provided protected salicylihalamides A 
118 in 81% yield and as a single isomer. 
 
 
 
 
 
 
 
 
Scheme 23.       Smith’s N-acylation of enecarbamate 11750 
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 De Brabander and co-workers59 reported an alternative pathway to the dienyl 
enamide via a lithium precursor instead of a cuprate species (Scheme 24). The first total 
synthesis of (+)-salicylihalamides A features a late-stage vinyllithium addition to an 
isocyanate for the installation of the enamide side chain. The hexadienyllithium 124 
prepared in situ by metal-halogen exchange from 123 was added to a solution of 
isocyanate 125 to afford compound 126 as an inseparable mixture of (22Z)- and (22E)-
isomers in 20% yield together with a dimer resulting from the addition of the intermediate 
lithium amide to the isocyanate 125. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 24.       De Brabander’s hexadienyllithium addition to the isocyanate 12559 
 
Unlike the salicylihalamides that have an enamide side chain that terminates in an α,β-
unsaturated alkyl chain, oximidines have a enamide side chain that terminate in O-
methyloxime. Kitahara’s group60 described a strategy for an efficient stereocontrolled 
introduction of the (Z)-enamide side chains of oximidines (Scheme 25). Exposure of the 
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known alcohol 127 to n-butyllithium followed by addition of iodine and manganese 
dioxide gave the aldehyde, which was subsequently transformed into the corresponding O-
methyloxime 128 by treatment with O-methylhydroxylamine hydrochloride. Completion 
of 130, the vinyl lithium coupling partner of (Z)-acyl azide 133, was achieved in two steps. 
Treatment of a solution of isocyanate 133 in toluene with reagent 130 allowed for the 
assembly of the two fragments providing the desired (Z)-enamide 134.   
  
 
 
 
 
 
 
 
 
 
Scheme 25.      Kitahara’s synthesis of the model oximidine side chain 13460 
 
 One year later the same group reported a facile method for stereoselective synthesis 
of (Z)-enamides,61 particularly, indolic enamide compounds, when they accomplished the 
total syntheses of coscinamides, chondriamides and igzamide. The synthesis of the key 
intermediate 138 of both Chondriamide A and C began with the protection of the aldehyde 
135 as the Teoc-carbamate by using Roush’s method to afford 136 (Scheme 26). After 
condensation of the latter with malonic acid the (E)-N-Teoc-3-indole-acrylic acid 137 was 
converted to N-Teoc-alkenylcarbamate 138 in 85% yield over three steps. Treatment of 
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138 with NaHMDS in THF, followed by addition of acid chloride 139 in THF gave the 
desired enamide 141 in 82% yield with retention of the configuration. Deprotection of the 
Teoc group with TBAF in THF provided chondriamide A (142). 
 Chondriamide C  (145) was also synthesized from the key intermediate 138 (Scheme 26). 
Irradiation of 138 with a high-pressure mercury arc lamp produced a mixture of the (Z)-
and (E)-alkenylcarbamates from which the (Z)-enamide 143 was isolated and subjected to 
NaHMDS, followed by addition of 139 to afford 145 in 79% yield with retention of the 
(Z)-configuration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 26.       Kitahara’s stereoselective synthesis of (Z)-enamide 14561 
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 Rizzacasa and co-workers62 applied a similar approach to the synthesis of the (+) 
Crocacin D by using NaH and phosphoryl azide to provide the N-acylazide 148 with 
minimal isomerization of Z-alkene; this is then followed by a Curtius rearrangement to 
give vinylisocyanate 149 (Scheme 27).63 Treatment of the latter compound with 
trimethylsilylethanol 150 provided the enecarbamate 151. Reaction of the anion derived 
from 151 with acid chloride 152 led to the protected enamide 153 in 32% yield. 
 
Scheme 27.       Rizzacasa’s stereoselective synthesis of enamide 15362 
 
 A convenient route to macrolides containing unsaturated enamide side chains is 
reported by Taylor64 and co-workers in an effort to synthesise the naturally occurring 
enamides Lansamide-I and  Lansiumamides A and B. The synthesis of Lansamide-I (159) 
is outlined in Scheme 28. This makes use of the cinnamic acid 154, which is converted to 
adduct 158 by addition of styryl Grignard 157 to the isocyanate 156.  
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Scheme 28.      Taylor’s synthesis64 of lansamide I 
 
 Under similar conditions as before, (Z)-cinnamic acid did not afford the desired 
(Z)-vinyl enamides and the only product that was observed was the isomerised E-adduct 
158. To prevent the unwanted vinyl isocyanate isomerization, Taylor’s group has explored 
the installation of a protecting group at the α-position of (Z)-cinnamic acid in an effort to 
maintain the stereochemistry as in 160 (Scheme 29). Reaction of the acid 160 with DPPA 
provided the acyl azide, which was converted into vinyl isocyanate. Addition of the styryl 
Grignard reagent 157 afforded a 1:1 mixture of (E)- and (Z)-vinyl enamides, of which the 
latter was used for the preparation of Lansiumamides A (163) and B (164). 
 
 
 
 
 
 
 
 
Scheme 29.      Taylor’s stereoselective synthesis64 of lansiumamide A and B 
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 1.6.4.1  Synthesis of unsaturated 2,4-(Z,Z)-heptadienoic amide  
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 Several examples of the synthesis of the highly unsaturated (Z,Z)-amide 101 
(Schemes 30 to 32) were reported in 2004 by Maier and Bayer.65  
 Their first approach to amide 101 started with bromination of trans–α,β- 
unsaturated carboxylic acid 167 which was converted to 2,3-dibromopentanoic acid 
followed by microwave irradiation to afford the corresponding (Z)-vinyl bromide 168 in 
excellent yield and high (Z)-selectivities.66  The metallation of 168 with lithium to the 
vinyllithium intermediate, followed by transmetallation with ZnCl2  afforded the precursors 
for the construction of the (Z,Z)-configurated ester 169. Aminolysis of the ester group 
provided the amide 101 in low yield (36%). 
 The second method is a variation of the Fürstner strategy (Scheme 31).67 First, the 
Z-iodoacrylate 166 was prepared by the reaction of lithium iodide with 2-propynoate (165) 
in acetic acid with both the stereoselectivity and yield depending on the reaction 
temperature.68 Cross-coupling reaction of butynylzinc (prepared from 171) with the (Z)-
methyl 3-iodoacrylate 166 followed by Lindlar reduction of the enyne 172 gave Z,Z-diene 
ester 169 in high yield. Finally, aminolysis of 169 converted it to amide 101 in low yield 
(36%) but changing the order of events (aminolysis of the ester 172 followed by Lindlar 
hydrogenation) dramatically improved the yield of the desired amide 101 to 80%. 
 The last approach to amide 101 by Maier and Bayer began with a methanol 
solution of the propiolamide 175 (prepared from methyl propiolate 174)69 that was coupled 
in the presence of CuCl with 1-bromobut-1-yne 171 providing the diyne 175 in 86% yield 
(Scheme 32). Lindlar hydrogenation of the latter provided (Z,Z) amide 101 in 80% yield. 
 Fürstner’s synthesis makes use of the Z-iodoacrylate 166 which was converted into 
the enyne 172 using a Negishi coupling reaction with butynylzinc chloride in catalytic 
condition (Scheme 34). Lindlar reduction followed by aminolysis of the resulting ester 169 
yielded the required amide 101 (62%). 
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Scheme 34.      Fürstner’s synthesis of 2,4-(Z,Z)-heptadienoic amide67  
 
 Labrecque et al. reported an alternative pathway to the amide 101 by using alcohol 
180 as the starting material (Scheme 35).47 Oxidation of the primary alcohol 180 with 
TPAP in the presence of NMO provided the unsaturated aldehyde 181 that was subjected 
to Horner–Emmons coupling reaction to afford the (Z,Z)-configurated ester 169 in 73% 
yield. The resulting ester was then hydrolyzed using barium hydroxide followed by 
amidation via mixed anhydride to afford amide 101 in 63% yield.  
 
 
 
 
 
 
 
 
Scheme 35.      Labrecque’s synthesis of 2,4-(Z,Z)-heptadienoic amide47 
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1.7  Installation of the enamide side chain 
1.7.1 Condensation of aldehydes and amides 
 
 The strategy used by Maier’s group58 in their total synthesis of salicylihalamides 
involved the elimination of water from a N-acylhemiaminal to give the enamide 
functionality, a reaction that usually gives mixture of isomers. Treating aldehyde 183 with 
aluminum carboximidoate, derived from amide 101 and DIBAL, gave the hemiaminal 184 
which underwent elimination of water upon treatment with acetic anhydride and pyridine 
to afford the desired (E)-enamide 185 in 45% yield along with 14% of the Z-isomer 
(Scheme 36).  
  
 
 
 
 
 
 
 
Scheme 36.   Preparation of enamide via Maier’s approach58 
 Starting with the same precursor but using different reaction conditions, Labrecque 
and co-workers47 installed the enamide side chain using the condensation of an excess of 
amide 101 with aldehyde 186 which provided the key intermediate N,N’-bis-acylated 
aminal (incorporating two side chain residues). The corresponding intermediate 187 
underwent elimination upon treatment with sodium hydride in trifluorotoluene at 60 oC to 
give a mixture of enamides 188a and 188b in 18% yield (Scheme 37).  
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Scheme 37.      Labrecque’s synthesis47 of enamides 188a and 188b 
 
1.7.2  Copper-mediated coupling reactions 
 Enamides are key structural features in a number of natural products. In addition to 
conventional approaches for their preparation, which has been mentioned previously in 
sections 1.5.4.1 and 1.5.4.3, a number of transition metal-catalyzed methods for the 
syntheses of enamides are known. However, these protocols often suffer from either low 
yields or are unable to control double bond stereochemistry. For these reasons, the copper-
catalyzed coupling of amides with vinyl halides appears to be widely applicable 
procedures in the total synthesis of natural products. This section is not intended to be 
exhaustive as it focuses on only a number of general and widely applicable procedures. 
 The basis of today’s developments of copper-mediated C-N, C-O, and C-C bond 
formation reactions was first reported more than a hundred years ago in the pioneering 
work of Fritz Ullmann and Irma Goldberg. In 1901 Ullmann reported the use of o-
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bromonitrobenzene for the synthesis of the corresponding biaryl 190 by direct coupling of 
two molecules of 189 in the presence of metallic copper (Scheme 38).70 
 
 
 
Scheme 38.      Ullmann reaction 
 The first copper iodide-catalyzed coupling reaction between vinyl bromides and 
potassium amides was successfully reported by Ogawa and co-workers71 (Scheme 39) in 
which enamide products were obtained in low to moderate yields by using stoichiometric 
amounts of copper(I) in HMPA at 130 °C. 
 
 
 
Scheme 39.      Cu(I)-catalyzed C-N bond construction by Ogawa et al.71 
   
 Based on this precedent, Porco and co-workers72,73 developed a copper-mediated 
amide vinylation method that occurred at mild temperatures and was suitable for the 
installation of potentially labile enamides. After screening a variety of catalyst systems, 
bases and solvents, they found that using the Liebeskind catalyst, copper(I) thiophene 
carboxylate (CuTC 193), cesium carbonate as base, and terminal (E)-vinyl iodides in polar 
aprotic solvents (NMP or DMSO) at 90 °C, a series of (E)-enamides could be prepared as 
shown in Scheme 40. Higher conversion (>95%) was obtained when the catalyst loading 
was increased to 30 mol % and the reaction mixture was rigorously degassed. 
As an extension of this methodology, the copper-catalyzed cross coupling process provided 
a guide for the design of another catalytic system based on ligand 194, Cu(CH3CN)4PF6 
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and Rb2CO3 in DMA (Scheme 40)74 starting from amides 195 and (E)-allyl 3-iodoacrylate 
196 or (E)-N-benzyl-3-iodoacrylamide 197. 
 
 
 
 
 
 
 
 
Scheme 40.      CuTC-Catalyzed coupling of vinyl iodides and amides74 
  
 Buchwald and co-workers75 have also reported the formation of enamides under the 
mild conditions and developed an experimentally simple and inexpensive catalytic system 
based on the use of 1,2-diamine ligand 198 (Scheme 41), K2CO3 or Cs2CO3 as base and 
substituted vinyl iodides 199 and bromides 200. This operationally simple protocol uses 
Cs2CO3, CuI as the catalyst and 198 as ligand in THF at temperatures ranging from 50 to 
70 oC when vinyl iodides 199 are used as substrates, whereas vinyl bromides 200 require 
the use of potassium carbonate in toluene at 110 oC. 
 
 
 
 
 
Scheme 41.      Formation of enamides under Buchwald’s conditions75 
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 In 2004, Coleman and Liu76 reported a unified strategy for the divergent and 
stereocontrolled introduction of the (E)- and (Z)-enamide side chains of oximidines I-III, 
salicylihalamides A and B, CJ-12,950, lobatamides A and D, all starting from vinyl iodides 
(E)-202 and (Z)-202 that can be prepared from isovaleraldehyde by Takai or Stork-Zhao 
olefination, respectively. Their strategy involved the use of a common intermediate (the 
cyclic hemiaminal 203) to prepare diverse members of a family of natural products 
(Scheme 42).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 42.      Strategy for the divergent and stereocontrolled introduction of the (E)- 
and (Z)-enamide side chains of family of natural products76 
 
A stereospecific copper-promoted C-N coupling of (E)-202 and (Z)-202 vinyl iodides with 
a protected maleimide hemiaminal 201 followed by deprotection gives the key 
intermediate 203. Reaction of the resulting (E)- or (Z)- enelactam hemiaminals with O-
methylhydroxylamine afforded the corresponding ring-opened O-methyloxime ether (Z)-
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205 (78%), characteristic of oximidine I and II, and (E)-205 (71%), characteristic of 
oximidine III, lobatamides, and CJ-12,950 while cis-selective Wittig olefination of (E)-203 
and (Z)-203 using propylidenetriphosphorane afforded (E)-206, characteristic of 
salicylihalamide A, and (Z)-206, characteristic of salicylihalamide B in high yields 
(Scheme 43). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 43.      Ring opening of the hemiaminals with O-methylhydroxylamine or 
propylidenetriphenylphosphorane. 
 
   With the development of new and efficient catalytic system that enable reactions 
to be conducted in mild conditions, the copper(I) thiophenecarboxylate mediated 
substitution of vinyl iodides with amides, has became a valuable strategy for the 
preparation of enamides. The utility of this synthetic strategy was later demonstrated in a 
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total synthesis of Lobatamide C 210 (Scheme 44).77 The key step featured a Copper(I) 
thiophenecarboxylate (CuTC, 193)-mediated vinylic substitution of 208 with (E)-O-
methyloxime amide 207 with base and additives and led to a 52% yield of the C1-C10 
enamide fragment 209, along with 10% of (Z)-oxime stereoisomer.  
 
 
 
 
 
 
 
 
 
Scheme 44.      Porco’s synthesis of lobatamide C77 
 
 It has been reported by Porco et al.78 in two separate publications the installation of 
the side chain of oximidines II 213 and III 215 by using a modified, ligand-assisted system 
(Scheme 45). Amidation of (Z)-vinyl iodide 211 with oxime amide 212 using standard 
conditions led to low yield due to competitive elimination under basic conditions, whereas 
the use of an additional ligand (N,N′- dimethylethylenediamine 198) allowed for a smooth 
coupling reaction. Oximdine II (213) was secured after desilylation in 44% yield and with 
high stereospecificity. Treatment of a 1/1 mixture of vinyl iodide isomers 214 with oxime 
amide 212 under the same conditions, gave after 1h a mixture (E:Z=7:1) of the required 
oximidine III in 45% yield.  Particularly in the latter case, extended reaction times resulted 
in decomposition of 215 and a higher yield of Z enamide.  
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Scheme 45.      Porco’s synthesis78 of oximidine II and III 
 
 The intermolecular cross-coupling reaction using Liebeskind’s promoter CuTC 193 
was next extended by the Nicolaou79 and Panek80 groups to the preparation of apicularen A 
(218). Su and Panek installed the highly sensitive enamide side chain at a late stage, using 
Porco’s protocol for the CuTC catalyzed substitution of vinyl iodide 211 with amide 101, 
which proceeded in 40% yield at 58 oC (Scheme 46). It was revealed that the reaction 
temperature and ligand-base combination were, as it is in a lot of cases, an important factor 
for the success of this coupling reaction.   
  A similar catalytic system was used in Nicolaou’s synthesis when ligandless 
conditions proved to be more efficient for vinylation of amide 101 with (E)-vinyl iodide 
219, which provided the desired apicularen precursor 220, with 90% yield at 50% 
conversion (Scheme 46). 
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Scheme 46.      Synthesis of apicularen A by Panek and Nicolaou groups79,80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 50 
Introduction Chapter 1
1.8    Structure-activity relationships of benzolactone enamide family  
 
 1.8.1     Salicylihalamide enamide analogues and biological activity 
 
 Salicylihalamide A, an interesting cytotoxic natural product, is a potent inhibitor of 
both vacuolar ATPase and proton pumps (IC50 below 1 nM)81 which are highly expressed 
in metastatic cancer cells82 where they modulate pH. De Brabander and co–workers83 have 
shown that the inhibition site(s) of salicylihalamides is within the membrane-bound V0 
sector of the V-ATPase where the inhibition is caused by blocking of the V0 proton 
channel through a mechanism distinct from concanamycin or bafilomycin. Evidence 
suggests84 that inhibition of these proton pumps eventually leads to cell deaths via 
apoptosis. In the course of their research to study the binding site of salicylihalamides and 
its mechanism, De Brabander’s group85 synthesized various analogues to perform some 
structure-activity relationship studies (SAR), identifying some structural characteristics 
that influence cytotoxic activity. The mechanism for the irreversible inhibition of the V-
ATPase proposed by De Brabander’s group is based on the N-acyliminium ion 222 
generated from N-acyl enamine 221 under acidic conditions (Figure 5). The iminium ion 
222 could then react with a nucleophilic amino acid side chain within the V-ATPase. The 
complex formed is then fragmented to a covalent protein 226 with loss of the side chain 
227.  
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Figure 5.      Proposed mechanism of irreversible inhibition of the V-ATPase protein 
by the enamide side chain. 81 
  
Some representative examples of the salicylihalamide and apicularen side chain modified 
analogues developed by De Brabander, Nicolaou86 and Maier are shown in Figure 6. 
 Based on extensive screening studies of systematically modified derivatives of 
salicylihalamide, it was revealed that side-chain-modified analogues 228-232 (Figure 6) all 
retain the ability to inhibit V-ATPase activity at concentrations similar to those of the 
parent compound with irreversible inhibition of the enzyme. The saturated hexane side 
chain analog 228 is almost equally as potent as salicylihalamide A but is ten-fold less 
active against the SK-MEL-5 melanoma cancer cell line. These studies also provided 
evidence that the hexadienoyl moiety did not affect the activity dramatically. When 
replacing the Z,Z-heptadienylamide with either 229 or 230 the analogues retained most of 
their activity. Additionally, it could be seen that the IC50 values increased with increasing 
the size and the bulkiness of the side chain, shown by the analogues 235-238.  
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 The structure-activity study of salicylihalamide analogues showed that the enamide 
subunit is responsible for potent inhibitory activity. Changing the N-acyl enamine 
functionality resulted in a significant loss of cytotoxicity as shown by analogs 233 and 235 
the latter being more than 1400 times less active than salicylihalamide A. It should be 
noted, however, that the enamide is important, but that modifications on the hexadienoyl 
fragment are tolerated up to 6-7 carbon atoms. 
 
 
 
 
 
 
 
Table 1.      Cytotoxicity values (IC50, nM) of several benzolactone enamides. 
 
A structure-activity study showed that the apicularen A, a highly cytostatic 12-membered 
macrolide, shares an identical, acid labile, N-acyl enamine side chain with salicylihalamide 
A. With respect to the important role of the enamide subunit, several analogues of 
apicularen A have been prepared and then tested against various cell lines, and the 
corresponding IC50 values are listed in Table 1 and Figure 6.  
 
 
 
 
µm 
Cell line                Origin                  Species            Api. A              Sali. A
                                                                                   (239)                 (1a)
L-929          connective tissue            mouse               6.8                    7
Y1              connective tissue             rat                     2.3                    23
KB-3–1       cervix carcinoma            human               2.3                  6.8
KB-V1       multiple drug-                 human               15.9                 9.1
                    resistant cell line
KB-V1       mdr cell line                     human               6.8                  6.8
                   +11      verapamil
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Figure 6. Salicylihalamide and apicularen enamide analogues and biological activity 
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 Furthermore the crucial role of the enamide moiety was confirmed by the loss of 
inhibitory activity of melanoma cell line SK-MEL-5 with analogues 240 and 246, while 
inverting the stereochemistry in the enamide olefin (247) resulted in a 100-fold loss of 
potency, respectively (Figure 6). Similarly as with salicylihalamide A analogues, 
substitution of the hexadienyl moiety with short aromatic chains (250 and 251) showed 
weak cytostatic affects relative to their congeners, whereas those analogues (248 and 249) 
with comparable side chain as that of apicularen A showed significant potency for cell 
inhibitions. 
 A careful analysis of a series of simplified analogs (252 and 261) reveals the 
importance of the macrolactone core for the biological function of salicylihalamide A 
(Figure 7). Blocking of either the phenolic hydroxy group (256) or the hydroxyl group on 
the macrolactone core (257) led to a decrease of activity by 60-fold and respectively by 
100-fold compared to that of the parent compound, suggesting the important role of the 
hydrogen-bonding in the enzymatic interaction between salicylihalamide and V-ATPase.  
 Smith and co-workers synthesized two modified macrolactone analogues (252 and 
253) and their results showed that while the removal of OH at C13 as well as the methyl 
group at C12 (252) had a moderate effect on the GI50 values (10-fold decrease from 
prostate cell-line DU-145), removal of the double bond reduced the activity slightly on 
several cell lines. They suggested that the removal of substituents from the lactone ring and 
the C-9 double bond might be important but not critical for the biological activity. 
 Following this work, a number of other simplified salicylihalamide analogues were 
synthesized in an attempt to evaluate whether the V-ATPase is a molecular target for 
cancer therapy. The results showed that fluorinated analog of salicylihalamide A (258) 
acted as a potent inhibitor of V-ATPase (IC50=2 nM), the truncated analogue 259 had only 
modest activity (1000-fold less active than the parent natural product), while the 
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macrolactone ether analogue 261 retained inhibition similar to the natural product but was 
weakly cytotoxic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.      Salicylihalamide core analogues and biological activity 
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  It can be concluded that none of the new analogues identified were more potent 
than the parent compound, however the minimum structural requirements for cytotoxic 
activity have been identified. The key elements necessary for a biological activity include: 
- changing the N-acyl enamine functionality attenuates the biological activity, but without 
the enamide subunit there is no inhibition of the V-ATPase protein; 
- the macrolactone ring is important and minor modifications in the aliphatic area cause only 
a small loss of activity; 
- the removal of the hydroxyl group on the macrolactone at C13 as well as the methyl group 
at C12 attenuates the biological activity; 
- the macrocyclic double bond is important but is not crucial for cytotoxicity; 
- the free phenolic hydroxyl group and the chiral center at C15 are essential for the 
cytotoxicity. 
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Chapter Two: 
Results and Discussion- 
Synthesis of a 15-aza-Salicylihalamide A 
Analogue 
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2.1 Initial considerations 
 
 In the course of ongoing investigations aiming at new drug candidates, we 
hypothesized that a new modification of salicylihalamide (1a) would be to change the 12-
membered macrolactone to a more stable macrolactam as in the 15-aza-salicylihalamide A 
analogue 301, that would be an interesting target for synthesis and biological evaluation. 
Is the lactam linkage less susceptible to cleavage than the lactone of the natural 
product? Would it impart stability to the macrolide system, possibly increase in vivo 
activity as was observed for the aza- epothilone? 
 The majority of SAR studies have been conducted on salicylihalamide derivatives 
with modified enamide side chains and it has been shown that the presence of some form 
of enamide functionality is critical for activity.  
What changes in the macrolactone are tolerated without substantial loss of 
cytotoxic activity? 
All these questions attracted our interest and we have launched into the synthesis 
and biological studies of the lactam analogue 301 of salicylihalamide A.  
  
 
 
 
 
 
 
 
 
 59 
Syntheis Chapter 2
O O
Ph Ph
O
H2N
O
101
266
PMBO
NH2
285
OAc
O
N OPMB
290
O
HN OPMB
OPG
265
O
HN NH
OH O
301
Cu cross-coupling
RCM
Photochemical
acylation
HO
O
OH
NH2O
278
2.2 Retrosynthetic analysis 
 
 A concise examination of the structure of compound 301 reveals a 12-membered 
salicylate macrolactam ring, an unusual N-acylated enamide side chain at C15 and an E-
endocyclic olefin at C9 as interesting structural motifs that need special attention from a 
synthetic point of view due to their stereochemical features. 
 Given these considerations, and some interesting structural issues which we hoped 
to address, we planned to utilize late-stage copper(I)-mediated cross-coupling of (E)-vinyl 
iodide derived from intermediate 265  with the known amide 101 to attach the enamide 
side chain (Figure 8). The macrolactam could be synthesised via a ring-closing metathesis 
reaction (RCM) conducted on diene 290. The critical amide bond could then be secured by 
a photochemical acylation between known dioxinone 266 and amine 285. This reaction 
involves the photolysis of 266, which produces an intermediate reactive quinoketene that is 
trapped by amine 285 to afford the amide 290. Amine 285 would be constructed from 
optically pure L-aspartic acid 278. 
 
 
 
 
 
 
 
 
 
Figure 8.      Retrosynthetic analysis of 15-aza-salicylihalamide A  
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Our proposed retrosynthetic approach for analogue 301 ultimately led to the alkene 266. 
The first part of the project therefore involves the synthesis of this intermediate for 
coupling to the amine 285.  
 
2.3 Synthesis of terminal alkene fragment 266 
 
 Following the synthetic pathway illustrated in Scheme 47 we began the synthesis of 
the alkene fragment from commercially available and inexpensive 2,6-dihydroxybenzoic 
acid 262. Initially we considered two protecting groups (acetone and benzophenone), 
which concomitantly mask both the carboxylic acid and one of the free hydroxyl 
moieties.88 It was anticipated that at this stage, the two benzodioxinones (265 and 266) 
would possess sufficient variation in reactivity to allow them to be photolysed in the 
presence of amine 285. As shown in the following section (section 2.5) using 
benzophenone proved to be a good choice. 
 
 
 
 
 
 
          [a] benzophenone, SOCl2, DMAP, DME, 44%; [b] Tf2O, CH2Cl2, pyridine, 96%; [c] LiCl, Pd(PPh3)4, 
           allyltributyltin, DMF, 74% 
 
Scheme 47.      A linear synthesis of alkene 266 
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Following a modified Hadfield’s experimental procedure,87 the synthesis of the 2,2-
diphenyl 1,3-dioxin-4-one (263) was attempted. In our hands initial attempts at this 
reaction gave the benzodioxinone 263 in very low yield (less than 20%). Allowing the 
reaction to stir for one hour upon completion of the addition of the reagents, as described 
in the reported procedure, had little effect on the conversion of symmetrical acid 262 to 
263 and purification of the latter by sublimation was found to be very difficult. A superior 
procedure, however, involved maintaining the anhydrous condition more efficiently and 
performing two recrystallizations from ethanol to provide a highly pure product not 
requiring chromatographic purification. A satisfactory yield of 44% was achieved. This 
benzodioxinone was then allowed to react with triflic anhydride and pyridine in 
dichloromethane, whereby the remaining hydroxyl group was converted to the 
corresponding triflate 264 in 96% yield. 
 Next, we directed our attention towards the substitution of an allyl group for the 
triflate group using a Stille-type reaction. 
 The Stille reaction89 involves the palladium-catalysed coupling of organotin 
reagents with a large variety of electrophiles and is now in widespread use in organic 
synthesis due to the stability to air and moisture of organostannanes and their compatibility 
with virtually any functional group. Various organic electrophiles can be used but halides 
and triflates are the most common due to their excellent leaving group properties. Typical 
palladium sources which have been used in such coupling reactions include Pd(PPh3)4, 
Pd2(dba)3, Pd(OAc)2, PdCl2(PPh3)2, PdCl2(PhCN)2, PdCl2(MeCN)2 with the most common 
being tetrakis(triphenylphosphine)palladium, which has shown excellent activity and 
functional group tolerance.90 The Stille reaction is complex and can follow different 
pathways depending on the solvent, additives (e.g. LiCl) and the nature of the substrates 
involved.  
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 At this point it would be useful to gain some insight into the mechanism of the 
Stille reaction before attempting an intermolecular coupling reaction between the precursor 
264 and allyltributyltin. 
 The generally accepted catalytic active complex involved in the Stille reaction is 
believed to be the 14-electron Pd(0) species L2Pd0 (Scheme 48).89 The initial step is the 
oxidative addition of the catalyst to the triflate 264 in which the organopalladium 
intermediate 264 a is formed, followed by transmetalation that has been established as the 
rate-determining step. To increase the reaction rate at which this process occurs, LiCl or 
Cu(I) salts are added. Finally, a reductive elimination reaction gives the coupled product 
266 and regenerates palladium(0) species to complete the catalytic cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 48.      General mechanism of the Stille cross coupling reaction89 
Catalyst: Palladium Source: Pd(PPh3)4 or Pd2(dba)3 
L= Ligand 
S= L or solvent 
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Taking advantage of the significant Stille methodology, we also wanted to take the 
opportunity to move away from THF, and run the reaction between the triflate 264 and 
allyltributyltin in DMF, a polar solvent that has been shown to promote reactions where 
moderately-polar THF had failed.92 Thus, the triflate 264 was allowed to react in a Stille 
fashion with allylstannane in the presence of catalytic Pd(PPh3)4 and LiCl in DMF at 80 °C 
to afford terminal olefin 266 in 74% yield. 
 Despite the versatility and synthetic utility of organotin reagents, a significant 
drawback of the Stille cross-coupling reaction is the difficulty in removing the tin by-
products from product mixture. In an effort to circumvent the problem associated with 
removing organotin impurities, we identified KF as a potential alternative to access the 
pure product.93 The incorporation of finely ground potassium fluoride into slurry silica gel 
used as a stationary phase for chromatographic purification of product mixture containing 
tin residues and a second chromatographic purification led to the isolation of the product in 
a high state of purity (Figure 9). 
Some product may have been lost during each purification step but it is of 
particular interest to note that under these conditions the desired product was easily 
separated from the organotin residue, as verified by the 1H NMR spectra. 
 
 
Figure 9.     1H NMR spectra of alkene 266: a) after KF-silica column and b) before 
silica column 
Tin residues 
a) b) 
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2.4 Synthesis of amine fragment 285 
 
 2.4.1 Model study towards the synthesis of primary amine 
 
 Initially, the most pressing research issue to be addressed was whether or not our 
key photochemical reaction would be feasible for an acylation coupling between chiral 
amine 285 and dioxinone 266 to form the amide 290 using a reported procedure.98 
 Before attempting the photoacylation of our authentic substrates, we decided to 
carry out a simple model study on a simpler amine. Although, later on, this amine had to 
be abandoned because it lacked the important chirality, it did help to trial the reaction 
conditions and to illustrate a few synthetic steps that were later incorporated into the 
synthesis of the genuine amine. 
 For the preparation of a model amine 277, the first key step involved protection of 
the commercial 3-butene-1-ol (267) as its p-methoxybenzyl (PMB) ether 270 as shown in 
Scheme 49.  
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Scheme 49.      Synthesis of model amine substrate 277 
 
 
The mono-PMB-protected olefin 270 was then smoothly and efficiently epoxidized with 
mCPBA to secure the epoxide 271 as a mixture of diastereoisomers (89% yield), that were 
inseparable on silica gel. Ring opening of 271 with the Grignard reagent 273 provided the 
alcohol 274 in 80% yield.50 Having obtained the desired precursor for the synthesis of 
Reagents and conditions:[a] HBr 48%, rt, 1h, 96%; [b] NaH, THF, 90%; [c] CH2Cl2, mCPBA, rt, 89%; 
[d] Et2O, I2; [e] Li2CuCl4, THF, 80%; [f] MsCl, NEt3, Et2O; [g] NaN3, DMF; [h] PPh3, DIAD, DPPA, THF, 
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amine fragment 277, efforts were focused towards the final product at this stage. The 
initial, motivating retrosynthetic thinking regarding the construction of the amine centered 
on the use of an azidation reaction. Two options were generally considered. Provided that 
an azide species could be generated from an alcohol in the presence of DPPA (an 
alternative to hydrazoic acid), DIAD and PPh3 using Mitsunobu conditions, a relatively 
easy reduction process of the azide group could then be used to form the amine 277 
(Scheme 49, method b). 
In the event that this reaction was not feasible, an alternative was to take advantage 
of the known ability of alcohols to be activated, followed by nucleophilic displacement of 
an oxy anion by azide and subsequent reduction would constitute a route for the synthesis 
of the target amine (Scheme 49, method a). 
Both methods allow for efficient preparations of amines: whereas the mesylation 
reaction seems to be a little bit more efficient because the crude mesylate can be used 
directly for the next step without further purification, the Mitsunobu approach was shown 
to have technical difficulties in the separation and purification of 276 before the azide 
group reduction to the amine. 
  The first approach (method a) is one step longer, but is both more efficient and 
reproducible with excellent yields for each step. Importantly, both strategies come together 
to a common amine precursor 276, adding flexibility to the synthesis. 
The alcohol 274 was then converted to azide 276 via a mesylation and azide 
displacement sequence. Mesylation of the alcohol using MsCl and triethylamine in the 
presence of diethyl ether, afforded the mesylate in 94% yield and its presence confirmed 
by the singlet at 2.95 ppm in the 1H NMR (Appendix B, page 146), corresponding to the 
methyl protons of the sulfonate group. Displacement of the mesylate using sodium azide in 
DMF afforded azide 276 in 90% yield. In the 1H NMR spectrum the multiplet at 3.5 ppm 
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moved upfield from its position in the mesylate at 4.9 (Appendix B, page 147). The 
observation of strong IR absorptions at 2096 and 1245 cm-1, corresponding to the azide 
group asymmetrical and symmetrical stretches respectively, confirmed the identity of the 
azide as 276 (Appendix A, page 135). 
Next in the synthesis was the conversion of the latter azide to the target amine. 
Reduction of the azide to the amine is a standard process and is of considerable importance 
for the introduction of primary amino group in organic synthesis, a process that could be 
done by using a variety of reducing agents.  
Initially, we tried to reduce the azide group to an amine group using trimethylphosphine as 
an alternative reagent of the Staudinger reaction, but we could not isolate the pure 
compound. After intensive trials of this reaction with no success this approach was 
abandoned. At that stage, a variety of azide reduction methods were surveyed with 
essentially no success. Consequently, alternatives were sought, and we decided to revisit 
the Staudinger reaction, the classical pathway to the iminophosphorane, a useful 
intermediate for the transformation of azides to amines when the reaction is carried out in 
an aqueous solvent.  
Gratifyingly, changing the reagent from trimethylphosphine to triphenylphosphine 
enabled amine 277 to be isolated in 65% yield after 3h at 70 °C.  
The disadvantage of this method was the formation of the very stable 
triphenylphosphine oxide byproduct that was generated in the reaction, which was difficult 
to remove, involving multiple chromatographic purifications. In an effort to circumvent 
this problem associated with this undesired byproduct, an extraction of the amine into 
aqueous HCl was sought. Two extractions with aqueous hydrochloric acid were necessary 
to recover more than 93% of amine 277 before neutralization and extraction into the 
organic layer. Concentration under reduced pressure gave amine product as an oil in a high 
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state of purity (65% yield). 1H NMR, 13C NMR, HRMS and IR spectroscopy analysis 
supported the structure of amine 277.  
 
2.4.2  Synthesis of chiral amine 285 
 
 The favorable outcome of our model study was encouraging. Having established an 
effective route to the requisite amine 277 and based on the insights gained from this model, 
we were prepared to test our model on the genuine substrate 278. To that end, we decided 
to use L-aspartic acid as a template for our synthesis that would allow us not only to reduce 
the number of steps, but also as a means of introducing the chirality with greater efficiency 
into 285. 
 The synthesis of the chiral amine required for the production of amide 286 began 
with commercially available L-aspartic acid 278, which was converted to bromosuccinic 
acid 279 using sodium nitrite in the presence of potassium bromide and sulfuric acid 
(Scheme 50).95  
 
 
 
 
Scheme 50.      Synthesis of diacid fragment 279  
 
Reduction of the diacid with borane dimethylsulfide complex afforded bromodiol 280 in 
88% yield. One–pot intramolecular cyclisation of the diol using NaH in THF afforded the 
corresponding epoxide, followed by the protection of the hydroxyl group as a PMB ether  
(Scheme 51).96 
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Scheme 51. Synthesis of epoxide fragment 281 
 
Applying the previously model study conditions, exposure of the enantiopure epoxide 281 
to the Grignard reagent (derived from 5-bromo-pent-1-ene) and Kochi’s catalyst50 
(Li2CuCl4) in THF led to an efficient ring opening of the epoxide providing alcohol 
product 282 in good yield (Scheme 52).  
 
 
 
Scheme 52. Synthesis of alcohol 282 
 
          A drawback of this synthesis is the use of the 5-bromo-pent-1-ene for the Grignard 
reagent, which is expensive to perform on a large scale. However, we were pleased to find 
that this reaction proceeded smoothly in 78% yield via attack of an in situ generated 
Grignard reagent on the epoxide.   
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To complete the synthesis of the azide, the free secondary alcohol in 282 was 
activated by mesylate formation (MsCl, NEt3, Et2O), and then converted to azide 284 
(NaN3, DMF) in 84% yield over two steps. The reaction was stereospecific and resulted in 
an inversion of the stereochemistry at C7 (Scheme 53) in accordance with a bimolecular 
nucleophilic substitution (SN2) reaction. The strategy has led to an efficient and 
stereospecific synthesis of the chiral azide 284. 
 
 
 
 
 
 
Scheme 53. Preparation of azide 284 
 
Following the success of the model reduction procedure reported in Scheme 49, the 
Staudinger reaction proceeded smoothly furnishing the desired amine product 285 as an 
oil, in good yield (65%) and in a high state of purity (Scheme 54). 
 
 
 
 
Scheme 54. Preparation of amine product 285 
 
Initial analysis by TLC indicated complete consumption of the starting material, 
and no IR absorbance in the azide range (2096 cm-1) had been observed for the product. 
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The IR spectrum displayed an absorbance at 3369 cm-1, validating the formation of the 
amine product 285 (Appendix A, page 136). In the 1H NMR spectrum the multiplet at 2.8 
ppm moved upfield from its position in the azide at 3.5 (Appendix B, page 149). 
 
2.5 Synthesis of amide fragment 286  
 
 The initial goal of the synthetic plan was to construct amide 286 (Scheme 56) in a 
stereocontrolled manner using the shortest and most efficient route possible. Before 
attempting the acylation of our authentic substrates, we decided to carry out a simple 
model study on 2,6-dihydroxybenzoic acid and different amines. To this end, we decided 
to investigate the possibility of protecting the phenolic hydroxyl groups or activating the 
acid as an acyl chloride followed by synthesis of the amide product (Figure 10). 
 
 
 
 
 
 
Figure 10. Various approaches to the amide product 
 
Initial attempts to construct the amide bond were explored by starting from 2,6-
dihydroxybenzoic acid and using different conditions with model substrates (Table 2). It 
should be noted that this acid is relatively unreactive due to steric hindrance exerted by two 
groups in the ortho position.  
 
 72 
H2N
H2N
OH
OH
O
Cl
OAc
OAc
O
Cl
1 
2 
no reaction 
no reaction 
A 
B 
A 
C 
activated Zn 
powder, toluene 
rt. 
 
microwave, 3h 
benzene 
 
Syntheis Chapter 2
OH
C
O
R1
R2
increased electron density
as a consequence
of the aromatic ring
 
 
 
    
 
 
 
 
Table 2.  Attempted salicylate amide formation 
 
The larger part of these traditional amine-acid coupling approaches relies upon  
activation of the acyl carbon allowing for greater access to the electrophile by the amine 
nucleophile under the reaction conditions. 
 Our attempts to install the amide bond using traditional amine-acid coupling 
strategies, proved unsuccessful. These attempts to link carbonyl group and amine in the 
acylation event were unsuccessful most likely due to steric hindrance of the ortho 
ester/hydroxyl groups which retarding the approach of the amine to the carbonyl group. 
 
 
 
 
 
Figure 11. Steric hindrance impeding the amine nucleophilic attack 
 
  Entry                               Substrates                                 Conditions                 Results 
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   These disappointing results led us to broaden our search of amidation methods to 
include less conventional approaches. As a result, we began to explore alternate strategies 
that would install the amide bond. Consequently, we elected to investigate the elegant 
photochemical method reported by De Brabander’s group, utilizing ketenes as useful 
intermediates in the synthesis of hindered ortho-substituted salicylate amides under 
essentially neutral conditions. In view of this finding and previous work by our group88 we 
decided to utilize the highly reactive quinoketene intermediate for the photochemical 
acylation reaction to acetonide 265 leading to the formation of salicylate amide 265 A in 
12% yield (Scheme 55).  
 
 
 
 
 
Scheme 55.      Photochemical acylation of the diene precursor 26588 
 
 The low yield of this reaction could be attributed to the poor radical stabilization by the 
dimethyl group in acetonide 265. To improve the radical stability and therefore the yield of 
this photochemical reaction, the methyl groups were replaced by the phenyl groups, 
generating benzodioxinone 266 (Scheme 56). 
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Scheme 56.      Photochemical acylation of the diene precursors 
 
When dioxinone 266 was photolysed, the in-situ generated quinoketene 287 was captured 
by the amine 285 and the yield of 286 improved to 20% supporting the claim that the 
ortho-quinoketene intermediate generated from 266 was more efficient leading to the 
formation of the desired 286 amide product (Scheme 57). 
These results add support to the original proposal98 that the quinoketene 287 is most likely 
formed by homolytic C–O bond fission, since an intermediate diphenylmethyl radical 
would be more stable than the dialkyl analogue. The proposed reaction mechanism is 
detailed in Scheme 57, whereby formation of the biradical 266 a and elimination of the 
benzophenone molecule is followed by formation of hydrogen bonded complex 287.  
Rearrangement of the 287 a and 287 b provided the amide product 286.  
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Scheme 57.    Proposed reaction mechanism of photolysis via quinoketene inermediate 
 
Several attempts were made to optimize the reaction conditions for this transformation, 
such as varying the benzodioxinone to amine ratio from 1.5:1 to 2.5:1 or changing the 
concentration of the reagents. 
After much optimization studies it was found that the most favorable conditions for 
this reaction were using a reaction time of 6 h, 1.5 equivalent of benzodioxinone, a 
concentration of 0.04 M, in a non-polar solvent and using a quartz reaction vessel (which 
allows more of the light to pass through) instead of a borosilicate test tube. Employing 
these conditions, the conversion of the required salicylate amide 286 was raised to 55% 
yield. To date, this reaction remains challenging but this approach to the required salicylate 
amide is notably short, efficient, and scalable. 
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The IR spectrum showed a broad absorbance at 3240 cm-1, indicating presence of the 
hydroxyl and also an absorbance at 1632 cm-1, providing confirmation of the amide bond 
(Appendix A, page 137). The 1H NMR spectrum of 286 displayed all the expected 
resonances, indicated a one proton singlet at 10.65 ppm (corresponding to phenolic 
hydroxyl) as well as a six proton in the alkenyl range of 6.05-4.90 ppm. Non-protonated 
13C NMR signal at δ 169.2 ppm indicated that a carbonyl group was present in the product 
(Appendix B, page 151). 
 
2.6 Ring closing metathesis reaction 
 
With diene 286 in hand, the stage was set for the exploration of the key step in 
forming the macrolactam 293. To construct the unsaturated 12-member macrolactam core 
with an isolated (E)-double bond configuration, we relied on a ring closing metathesis 
reaction (RCM) of diene substrate 286. While RCM has been demonstrated to be a 
versatile technique in carbon-carbon double bond formation it is important to note that the 
prediction and control of stereoselectivity of the reaction is often challenging and usually 
provides a mixture of the (E)- and (Z)- isomers. 
Several studies have been published on this RCM reaction,48,77,86,100 all of which 
revealed the influence that functionality remote from the double bond in the RCM can 
affect the E/Z-ratio of the configured cyclic olefins. It is worthy to note that Fürstner 
speculated that the hydrogen bond between the phenolic hydroxyl and the carbonyl group 
most likely was responsible for influencing the stereochemical outcome of the cyclization. 
Other studies directed toward the synthesis of salicylihalamide A81,86 have shown 
that using the appropriate ruthenium catalyst could exert control of the double bond 
geometry.   
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Based on these observations, we decided to introduce an appropriate protecting 
group to mask the aromatic free hydroxyl group in 286 to favor the formation of the 
desired E-isomer.  
The exploration of the stereoselective formation of macrocyclic E alkenes involved 
a different subset of protecting groups at the phenol position to enhance the E:Z selectivity 
of the ring-closing metathesis reaction. The list of potential protecting groups was rather 
long, but limited to groups that could be easily removed at a later stage and were tolerant 
of basic and oxidative conditions. We considered that the three best candidates were TBS 
ether, methyl and acetyl protecting groups, although the exact nature of the protecting 
group had little effect on the RCM cyclization (Scheme 58).  
 
 
 
 
 
 
Scheme 58.      Protection of the phenol group in 286 
 
Treatment of 286 with TBSCl in imidazole and DCM afforded the desired TBS 
protected product 288 in 68% yield while exchanging TBS silyl ether for a methyl group 
(using MeI and K2CO3 in acetone) provided 289 in a better yield (88 %). In contrast to the 
previous results, the use of an acetyl-protecting group proved to be exceptionally efficient 
(90% yield) and could be used for the next step without purification. Consequently, we 
chose to use an acetyl-protecting group for our ring-closing metathesis. 
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Recrystallisation of 290 from CH2Cl2/pentane gave small crystals suitable for X-
ray diffraction. Single crystal X-ray analysis confirmed the absolute configuration as R and 
allowed an unambiguous assignment of the molecular structure of 290 to be made (Figure 
12).  
 
 
 
 
 
Figure 12.      Absolute stereochemistry of acetate 290 
 
The structure corroborates the data from 1H NMR, 13C NMR, IR spectroscopy and HRMS 
analysis. The appearance of IR absorption at 1764 cm-1 for the ester carbonyl functional 
group of 290, along with the disappearance of absorption at 3240 cm-1 for the alcohol 
functional group of 286, was observed to confirm that acylation was successful (Appendix 
A, page 138). The methyl singlet at δ 2.27 in 1H NMR and the carbonyl signal at δ 165.5 
ppm in 13C NMR positively confirmed the presence of acetyl group in 290 (Appendix B, 
page 153). 
Having constructed the key element of the RCM precursor 290, the stage was set to 
explore the reactivity of this compound for macrocyclisation. In regard to the construction 
of the macrocyclic ring, the RCM reaction was conducted on 290 using the highly active 
ruthenium-based catalyst A and B (Scheme 59).  
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Scheme 59.      Synthesis of the macrolactam core using RCM 
 
There was no evidence for the formation of RCM product when diene 290 was 
treated with Grubbs 1st generation catalyst (A) in toluene at room temperature; when 
increased to the reflux temperature of toluene, decomposition occurred. All other attempts 
using Grubbs 2nd generation catalyst (B) in refluxing toluene also did not produce any 
desired product. 
In order to address this lack of reactivity we decided to attempt the cyclization in a 
different solvent using same catalysts and substrate.  
As previously mentioned, we expected that the stereochemical outcome to be 
determined during the cyclisation in which the protection of the phenolic hydroxyl group 
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enrty             substrate              t(h)            yield(%)               E:Z
1
2
3
288
289
290
24
24
24
34
65
77
64:35
72:28
87:13
Tabel 3.  RCM studies of 287 to 295. All reaction were carried out 
using Grubbs 1st generation catalyst A (1 mol%) in CH2Cl2
Ratio E:Z determined by 1H NMR analysis
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would have a major role. Thus, when the phenolic hydroxyl group in 286 was protected as 
the tert-butyldimethylsilyl (TBS) ether, using CH2Cl2 and Grubbs 1st generation catalyst 
(A), we were able to form the macrolactam 291, with E-isomer predominating (Table 3).  
 
   
 
 
 
 
 
 
A methyl or acetyl phenol protecting group produced similar outcomes. Treatment of 290 
with ruthenium catalyst A in refluxing CH2Cl2 under rigorously anhydrous and air-free 
conditions afforded the desired macrolactam (E)-293 as the major product, and was 
isolated in 66% yield while (Z)-296 could be separated from the E-isomer by flash 
chromatography in 10% yield.  
 It should be noted here that when the reaction was performed using the second-generation 
Grubbs’ catalyst B (1mol %) in CH2Cl2, the results were comparable, contrary to what has 
been reported in the literature (Grubbs 2nd generation catalyst had been shown to favor 
production of the Z-configured product).48   
The well-established mechanism of the ring-closing metathesis of diene 290 is an 
intramolecular process and consists of two successive metathesis reactions (Scheme 60). 
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Scheme 60.      The mechanism of ring-closing olefin ruthenium-catalyzed metathesis 
 
Initially, the synthesis of 293 was not very satisfactory as yields were in the 45% 
range and the macrolcyclisation reaction performed poorly on scale-up above 300 mg. In 
an effort to optimize the reaction conditions, we found that by adding a solution of the 
ruthenium catalyst A (1mol%) (via cannula over a 5 min period) to the RCM substrate in 
CH2Cl2  at 45 °C, the yield of the reaction increased (the addition sequence was important 
for this reaction). Finally it was found that performing the reaction in a more diluted 
solution (substrate concentration of 0.005g/mL CH2Cl2 versus 0.05g/mL CH2Cl2) 
improved the yield to 77%.   
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The assignment of the protons in E-endocyclic alkene system of 293 is based on the 
analysis of the signals in the 1H NMR spectrum where the H(10) proton appeared at δ 5.26 
(dddd) and exhibited a trans coupling of 14.9 Hz with H(9) at δ 5.50. The 1H NMR 
spectrum of Z-olefin system possessed the expected signal from the H(9) proton which 
appeared at δ 5.46 and exhibited a cis coupling of 10.3 Hz with H(10) at δ 5.18 (Appendix 
B, page 157). Mass spectrometry data also confirmed the formation of the E (293) and Z 
(296) product, with a peak at 474.22504 m/z, which is the calculated mass plus a sodium 
ion. 
Ruthenium catalysts A and B despite of their importance in the preparation of 
macrocyclic rings and of their remarkable tolerance of different organic functional groups, 
share some disadvantages. The colored and toxic ruthenium byproducts are difficult to 
remove completely from the reaction products even after purification by column 
chromatography. 
Several interesting protocols to remove ruthenium-related byproducts have been 
reported. Use of DMSO,101 oxidation of the ruthenium products with lead tetraacetate102 or 
the use of a combination of silica gel and activated charcoal103 were reported to reduce the 
ruthenium content in the crude product. 
In view of reported methods we applied the last procedure to our crude product and 
found that after stirring with activated charcoal for 12 h at room temperature followed by 
silica gel column chromatography, the level of ruthenium byproduct was reduced 
dramatically. 
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2.7  Synthesis of the vinyliodide fragment 299  
 
Having secured an effective sequence to the macrolactam 293, we set out to 
prepare vinyl iodide 299, for a copper (I) mediated cross-coupling reaction with 101 to 
complete the synthesis. Therefore, benzolactam 293 was deprotected by oxidative cleavage 
of the p-methoxybenzyl ether using 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) under 
pH 7.0 buffered conditions (6:1, CH2Cl2/pH 7.0 buffer) to give the primary alcohol at C17 
in 84% yield (Scheme 61).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 61. Synthesis of the vinyl iodide 299 
 
Monitoring the reaction by TLC showed that the cleavage of the protecting group 
went to completion and alcohol 297 was formed after 2 hours and the crude product was 
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OAc
O
HN OH
298
purified by flash chromatography to afford the primary alcohol as a white solid in 84% 
yield.  
The resulting primary alcohol 297 was then oxidized using the Dess-Martin reagent 
to yield the corresponding aldehyde 298 required to carry out the necessary Takai 
olefination to provide the E-vinyl iodide 299 for the final coupling step (Scheme 61).  
We chose to use Dess-Martin periodinane as it has been reported to be non-acidic and also 
the most reliable reagent for oxidation of primary alcohols to aldehydes under mild 
conditions. 
The addition of four equivalents of Dess-Martin periodinane in one portion to 
alcohol 297 in CH2Cl2 at 0 oC gave aldehyde 298 in 90% yield. Colorless crystals of 298 of 
suitable quality and size for X-ray structural analysis were obtained from recrystallization 
from EtOAc at room temperature, giving, once again, the opportunity to confirm the 
absolute stereochemical configuration at C15 (Figure 13). 
The 1H NMR spectrum showed the aldehyde proton as a triplet at δ 9.81 (J 2.1 Hz) 
whereas the aldehyde carbon atom appeared at δ 200.4 in the 13C NMR spectrum 
(Appendix B, page 161). The IR spectrum of 298 showed the aldehyde carbonyl absorption 
at 1724 cm-1 (Appendix A, page 142). The X-ray crystal structures of 298 also showed that 
the endocyclic alkene in the 12- membered ring possesses the E geometry. 
 
 
 
 
 
 
Figure 13.      Absolute stereochemistry of aldehyde 298 
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At that point, there was sufficient material to continue with the synthesis of the vinyliodide 
compound. 
A literature search revealed that a stereoselective method for the conversion of 
aldehyde to the corresponding (E)-vinyl halides have been published in 1986 by Takai et 
all. 99 The reaction involves the use of CHX3 (X=I, Br or Cl) and the chromium salt, CrCl2, 
usually in large excess. 
Since an E-iodolakene was required, we chose the Takai reaction as it is known to 
be highly E stereoselective. Using the chromium-mediated approach, aldehyde 298 was 
subjected to a Takai iodo-olefination by treatment with CHI3 and CrCl2 in THF to 
furnished the desired trans-iodo-olefin 299 as an inseparable mixture of isomers (E:Z in a 
ratio of 8:1) as determined by 1H NMR analysis (only one single spot was visible on the 
TLC plate for both isomers). Regarding the result of this one-carbon homologation 
reaction, one should keep in mind a practical and important parameter: the outcome was 
highly dependent on the quality of the CrCl2 knowing that this reagent is very hygroscopic 
and air-sensitive.  
A possible mechanism has been suggested for this reaction, involving a geminal 
dichromium reagent (D) formation as the key step, followed by addition of the aldehyde to 
afford the organometallic compound 298 A which then eliminates to give olefin 299 with 
mainly E geometry in 72% yield (Figure 14). 
The 1H NMR spectrum of the vinyliodide 299 showed the H(17) signal resonace at 
δ 6.37 (dtd) and exhibited a trans coupling of 14.3 Hz with H(18) at δ 6.09. Mass 
spectrometry data also confirmed the formation of the olefin product 299, with a peak at 
476.06950 m/z, which is the calculated mass plus a sodium ion. 
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Figure 14.      Proposed mechanism for the Takai homologation reaction 
 
2.8 Completion of the total synthesis of 15-aza-salicylihalamide A analogue 
 
Having completed the efficient synthesis of 299 and heptadienyl amide 101, attention was 
focused on the coupling of both fragments. 
According with our proposed retrosynthetic approach (Figure 8, Section 2.2), the 
assembly of iodo-olefin 299 and amide fragment 101 was planned to be done at a late stage 
in the synthesis with the latter fragment synthesized according to the protocol developed 
by Fürstner el al67, Maier et al69 and Erickson et al118 (Chapter 1, Scheme 33). 
To assess the utilization of copper-mediated coupling reaction, we commenced 
with a model study to determine the most practical method to convert an iodo-olefin into  
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an enamide. Heptamide 300, a readily available starting material prepared from heptanoic  
acid and urea, served as a coupling partner of iodo alkene 299. Originally we had proposed 
that the coupling of these two fragments would be accomplished via a modern variant of 
the Goldberg reaction developed by Porco and co-workers.73 This group used an efficient 
approach to the assembly of enamides using Liebeskind catalyst (copper(I) thiophene 
carboxylate) as a source of Cu(I), Cs2CO3 or K2CO3 as base and NMP, DMA or DMSO as 
a polar aprotic solvent (Chapter 1, Section 1.7.2.1). Consequently, we applied the reported 
reaction conditions to our system (entries 1-6) but our attempts to assemble the enamide 
moiety failed (Table 4).  
As a result, we turned our attention to alternative strategies to install the enamide 
side chain. To that end, we explored the Buchwald protocol that used the used the ligand 
N,N’-ethylenediamine and Cs2CO3  in THF at temperatures ranging from 50 to 70 oC.  
However, in the few trials run under these conditions (entries 7-9, Table 4), no reaction 
occurred as monitored by TLC and confirmed by 1H NMR analysis.  
Various attempts were made to optimize the reaction, such as freshly distilled 
solvent, varying the heating times and changing the equivalents of the reagents, but 
unfortunately, under this variety of conditions we were unable to achieve the task.  
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HN H NH
H2N
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O
see table
reagents result
CuTC; Rb2CO3; DMA; 90 oC; 12h No reaction
CuTC; Cs2CO3; NMP; 90 oC; 2h
CuTC; Cs2CO3; dioxane; 90 oC; 18h
CuTC; Cs2CO3; toluene; 90 oC; 12h
CuTC; K2CO3; NMP; 90 oC; 2h
No reaction
No reaction
No reaction
No reaction
CuTC; Cs2CO3; DMA; 90 oC; 2h No reaction
OH
O
urea, 180 oC, 4h H2N
O
entry
1
2
3
4
5
6
7
8
CuI; K2CO3; N,N'-ethylene diamine, THF, 110 oC No reaction
CuI; Cs2CO3; THF; 80 oC No reaction
S
OCu
O
CuTC
300
300
299
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.      Study of attempted copper-mediated coupling reaction conditions 
 
The inability to advance our model system to the enamide formation, prompted us 
to speculate that the absence of conjugated dienes in the amide model 300, prevented the 
copper-mediated C-N bond formation from occurring. As a result we decided to use the 
real amide 101 (prepared from propionaldehyde 176 in five steps,65,67,94 Scheme 33 ) in the 
synthesis of the new analogue.  
Cross coupling of iodide 299 with dienamide 101 was conducted under the 
conditions developed by Buchwald104 and utilised in a recent total synthesis of the related 
compound apicularen A.105 This reaction formed the desired enamide and resulted in the 
concomitant cleavage of the phenolic acetate to provide the analogue (−)-301 in 64% yield 
(Scheme 62). 
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Scheme 62.      Completion of the total synthesis of 301 
 
The mechanism of copper-catalyzed C-N bond-forming reaction between N-nucleophile 
101 and vinyl iodide 299 is shown in (Scheme 63).109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 63.      Proposed mechanism for the Cu(I)-catalyzed N-Alkylation of 
dienamide 101109 
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The 1H NMR spectrum of the analogue 301 showed the signal of H(17) at δ 5.41 
(m) and the proton H(18) appeared as a doublet at δ 6.80 and exhibited a trans coupling of 
J = 14.4 Hz with H(17) (Appendix A, page 165). The corresponding signal in the 13C NMR 
spectrum for C(17) was observed at δ 112.1 and that of C(18) at δ 126.3 whereas C(20) 
signal appeared at δ 120.6 (Appendix B, page 166). In the IR spectrum the absorption of 
the OH group appeared at 3348 cm-1 along with the disappearance of absorption at 1760 
cm-1 for the ester carbonyl functional group of 299 (Appendix A, page 143). Mass 
spectrometry data also confirmed the formation of the analogue 301, with a peak at 
431.23053 m/z, which is the calculated mass plus a sodium ion. 
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Scheme 64.      Complete synthetic route of 15-aza-salicylihalamide A analogue 
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2.9      Biological assays1 
 
The analogue 301 was assayed against the NCI-60 leukaemia cell lines [i.e. CCRF-
CEM (acute lymphoblastic leukaemia), HL-60 (acute promyelocytic leukaemia), K562 
(chronic myeloid leukaemia), MOLT-4 (acute lymphoblastic leukaemia) and RPMI 8266 
(myeloma)] and exhibited antiproliferative effects at sub-micromolar concentrations (Table 
5). For comparison, bafilomycin A1 (Figure 15) was also assayed against the same cells 
lines since both this compound and salicylihalamide A (1) target vacuolar-type (H+)- 
ATPase in the lysosome.38,106,107 Compound 301 was very active against MOLT-4 (IC50 = 
277 nM) and CCRF-CEM (IC50 = 371 nM) but was most active against RPMI 8226 and 
HL-60 (IC50 = 117 and 116 nM for each respectively). 
 
Bafilomycin A1 was approximately 10 fold higher in activity than the aza-salicylihalamide 
analogue 301 across all the cell lines. In addition, the sensitivity profiles of bafilomycin A1 
and analogue 301 were strongly correlated (Figure16) supporting a similar mode of action 
against vacuolar-type (H+)-ATPase.1 
 
 
                                            
1  We thank Professor David C. S. Huang (Walter and Eliza Hall Institute of Medical Research, Parkville, 
Victoria) for the biological assays of the analogs. 
Cell line Compound 301 
IC50 (nM) 
Bafilomycin A1 
IC50 (nM) 
CCRF-CEM  371 ± 39 30 ± 1 
HL-60  116 ± 14 17 ± 1 
K562  506 ± 47 43 ± 15 
MOLT-4  277 ± 9 23 ± 1 
RPMI-8226  117 ± 4 13 ± 1 
Table 5       Growth inhibitory activities of compound 301 and bafilomycin A1 
Figure 15. Bafilomycin A1 O
HO OH
OH
OMe
OH
O
O
OMe
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Fig 16.    Sensitivity of NCI-60 leukemia cells to bafilomycin A1 versus the aza-  
               salicylihalamide analogue 301 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bafilomycin A1 (27) was approximately 10 fold higher in
activity than the aza-salicylihalamide analogue 3 across all the
cell lines. In addition, the sensitivity profiles of compound 27
and analogue 3 were strongly correlated (Fig. 2) supporting a
similar mode of action against vacuolar-type (H+)-ATPase.
Conclusions
The aza-salicylihalamide analogue 3 was synthesised for the first
time in a short sequence that is amenable to large scale. Key
steps include a photochemical acylation to form the amide
linkage, a E-selective ring closing metathesis to secure the
macrolactam and a Cu mediated cross coupling to introduce the
enamide and remove the phenolic acetate. Analogue 3 showed
potent activity against several leukemia cell lines correlating
strongly with bafilomycin A1 (27) and shows promise for further
development as an anti-cancer compound. The preliminary bio-
logical results demonstrate that the introduction of a stable
lactam linkage in the salicylihalamide structure affords a potent
simplified analogue 3 of this family of compounds which com-
pares well to other reported analogues and the natural product
itself. Further tests to determine the in vivo activity and stability
of this compound and derivatives are underway.
Experimental
General
Optical rotations were recorded in a 10 cm microcell. High resol-
ution mass spectra (HRMS) were run using electrospray ionis-
ation (ESI). Proton nuclear magnetic resonance (1H NMR,
300 MHz) and proton decoupled carbon nuclear magnetic reson-
ance spectra (13C NMR, 75.5 MHz) were recorded for deuterio-
chloroform solutions with residual chloroform as internal
standard unless otherwise stated. Analytical thin layer chromato-
graphy (TLC) was conducted on aluminium backed 2 mm thick
silica gel GF254. Compounds were visualized with solutions of
20% w/w phosphomolybdic acid in ethanol or under UV
(365 nm). Anhydrous tetrahydrofuran (THF) and diethyl ether
were dried using a Glass Contour cartridge solvent dispensing
system. All other commercial reagents were used as received. All
air and moisture sensitive reactions were performed in glassware
that was either flame dried under an atmosphere of dry argon or
oven dried at 150 °C.
Amide (14)
A solution of the and amine 1314 (350 mg, 2.04 mmol) and the
benzodioxinone 913 (1.34 g, 4.08 mmol) in CH2C12 (8 mL)
under N2 was placed in a Rayonet photochemical reactor
equipped with 16 × 300 nm lamps and the solution was irradiated
for 4 h. The solvent was removed under reduced pressure and
the crude product purified by flash chromatography with 15%
EtOAc/petrol as eluent to afford the amide 14 (308 mg, 55%) as
a white solid. Rf (20% EtOAc/hexane) 0.39; νmax: 3258, 3077,
1747, 1631, 1588, 1533. δH 10.69 (1H, s) 7.24 (1H, t, J = 7.6
Hz), 6.85 (1H, d, J = 8.0 Hz), 6.68 (1H, d, J = 7.2 Hz), 6.59
(1H, br s), 6.14–6.23 (1H, m), 5.74–5.84 (1H, m), 5.28 (1H, dd,
J = 10.4, 1.6 Hz), 5.01 (1H, dd, J = 10.0, 2.0 Hz), 4.96 (1H, dd,
J = 10.0, 2.0 Hz), 4.94 (1H, dd, J = 9.6, 1.6 Hz), 3.52 (2H, m),
3.40 (2H, q, J = 5.6 Hz), 2.05 (2H, q, J = 6.8 Hz), 1.57 (2H, m),
1.31–1.47 (4H, m); δC 169.7, 159.6, 138.5, 138.4, 136.0, 132.0,
122.8, 118.5, 117.7, 115.9, 114.6, 39.8, 38.6, 33.5, 29.0, 28.4,
26.4; HRMS (ESI) calc for C17H23NO2Na [M + Na]
+ 296.1621,
found 296.1621.
Azide (18)
To a solution of alcohol 17 (2.4 g, 8.6 mmol) in Et2O (60 mL) at
0 °C was added triethylamine (4.23 mL, 30.2 mmol) and metha-
nesulfonyl chloride (2.33 mL, 30.2 mmol). After 15 min of stir-
ring at 0 °C the reaction mixture was warmed to room
temperature and the reaction was left to proceed for further 2 h.
Then the resulting mixture was quenched with water, the organic
layer was separated and the aqueous solution was extracted with
Et2O (3 × 50 mL). The combined organic extracts were washed
successively with 50 mL H2O and 50 mL sat. aq. NaCl, dried
over Na2SO4 and concentrated affording the crude mesylate
(2.88 g, 94%) directly used for the next step without further
purification. To a solution of above mesylate (2.80 g,
7.86 mmol) in DMF (30 mL) was added NaN3 (1.12 g,
17.3 mmol) and the mixture was stirred at 72 °C for 20 h. After
cooling to room temperature the reaction mixture was quenched
with water and extracted with diethyl ether (3 × 50 mL). The
combined organic extracts were washed with water and brine and
dried over MgSO4, filtered and concentrated in vacuo to give the
crude product, which was purified by flash chromatography with
10% Et2O/hexane as eluent to give azide 18 (2.14 g, 90%) as a
colourless oil [α]26D − 27.8 (c 1.12, CH2Cl2); Rf (10% Et2O/
hexane) 0.58; IR νmax: 2933, 2858, 2096, 1612, 1512, 1245,
1089, 1034, 910, 819 cm−1; δH 7.30 (2H, d, J = 8.5 Hz), 6.92
(2H, d, J = 8.5 Hz), 5.84 (1H, ddt, J = 17.1, 10.2, 6.6 Hz), 5.03
(2H, m), 4.48 (2H, ABq, J = 11.6 Hz), 3.83 (3H, s), 3.59 (2H,
m), 3.54 (1H, m) 2.10 (2H, m), 1.79 (2H, m) 1.50 (6H, m); δC
158.9, 138.3, 130.0, 129.0, 114.3, 113.5, 72.5, 66.2, 59.8, 54.9,
34.4, 34.2, 33.3, 28.3, 25.2; HRMS (ESI) calculated for
C17H25N3O2Na [M + Na]
+ 326.18390, found 326.18396.
Amine (10)
To a solution of azide 18 (4.8 g, 15.8 mmol) and triphenylphos-
phine (16.9 g, 63.3 mmol) in THF (100 mL) was added water
Fig. 2 Sensitivity of NCI-60 leukemia cells to bafilomycin A1 (27)
versus the aza-salicylihalamide analogue 3.
Org. Biomol. Chem. This journal is © The Royal Society of Chemistry 2012
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2.10      Conclusions  
 
The aza-salicylihalamide analogue 301 was synthesised for the first time in a short 
sequence that is amenable to large scale. Key steps include a photochemical acylation to 
form the amide linkage, a E-selective ring closing metathesis to secure the macrolactam 
and a Cu mediated cross coupling to introduce the enamide and remove the phenolic 
acetate. Analogue 301 showed potent activity against several leukemia cell lines 
correlating strongly with bafilomycin A1 and shows promise for further development as an 
anti-cancer compound. The preliminary biological results demonstrate that the introduction 
of a stable lactam linkage in the salicylihalamide structure affords a potent simplified 
analogue 301 of this family of compounds which compares well to other reported 
analogues and the natural product itself. Further tests to determine the in vivo activity and 
stability of this compound and derivatives are underway. 
 
 
 
 
 
 
 
 
 
 
 
 95 
Experimental Chapter 3
 
 
 
 
 
 
 
 
 
 
 
Chapter Three: 
Experimental 
 
 
 
 
 
 
 
 
 
 
 96 
Experimental Chapter 3
 
Experimental Procedures  
I. General Techniques 
 
 Unless noted otherwise, commercially available materials were used without 
further purification. Solvents used for moisture sensitive operations were distilled from 
drying agents under a nitrogen atmosphere: Et2O and THF from sodium benzophenone 
ketyl; benzene and toluene from sodium; CH2Cl2, NEt3 and pyridine from CaH2. All other 
commercial reagents were used as received. 
Optical rotations were recorded in a 10 cm microcell. High resolution mass spectra 
(HRMS) were run using electrospray ionisation (ESI). Chemical shifts (δ) are given in ppm 
relative to residual solvent (usually chloroform; δ 7.27 for 1H
 
NMR or δ 77.5 for proton 
decoupled 13C NMR) and coupling constants (J) in Hz. Multiplicity is tabulated as s for 
singlet, d for doublet, t for triplet, q for quadruplet, and m for multiplet, whereby the prefix 
app is applied in cases where the true multiplicity is unresolved, and br when the signal in 
question is broadened. Infrared spectra were recorded on a Perkin-Elmer 1000 series FTIR 
with wavenumbers expressed in cm-1 using samples prepared as thin films between salt 
plates.  
Analytical thin layer chromatography (TLC) was conducted on aluminium backed 
2 mm thick silica gel GF254. Compounds were visualized with solutions of 20% w/w 
phosphomolybdic acid in ethanol or under UV (365 nm). All air and moisture sensitive 
reactions were performed in glassware that was either flame dried under an atmosphere of 
dry argon or oven dried at 150 °C. 
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II. Experimentals 
1.      Synthesis of terminal alkene fragment 8 
 
Benzodioxinone 26387,88 
 
 
 
 
To an oven dried flask containing 2,6-dihydroxybenzoic acid 262 (18 g, 116.8 
mmol, 1 equiv) and DMAP (2.13 g, 17.5 mmol, 0.15 equiv), ethyleneglycol dimethyl ether 
(100 mL) and benzophenone (31.91 g, 175.2 mmol, 1.5 equiv) were added under a 
nitrogen atmosphere. This solution was cooled to 0 oC and SOCl2 (14.42 mL, 198.5 mmol, 
1.7 equiv) was added dropwise with stirring over a period of 30 minutes. The mixture was 
allowed to reach room temperature slowly and stirred for 18 h and then quenched with 
saturated NaHCO3 solution. The solution was extracted with EtOAc (3 x 50 mL) and the 
separated organic layers were washed with water and brine, dried over anhydrous MgSO4 
and concentrated in vacuo. The residue was passed through a plug of silica gel using 
CH2Cl2/hexane 1:1 as the eluent. After removal of the solvent the solid was recrystallized 
from ethanol to give 263 (11g, 44%) as a white powder.  
The 1H NMR and 13C NMR spectra of 263 were identical with those reported in the 
literature.87,88 
TLC: Rf (50% CH2Cl2/hexane) 0.60;  
IR υmax: 3257, 3063, 1696, 1629, 1585, 1470, 1334, 1200, 1157, 1106, 1056, 810, 754, 
693 cm-1; 
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 1H NMR (CDCl3, 300 MHz): δ = 10.14 (1H, br. s, Ar-OH), 7.59 (4H, m, Ar-H, 2’, 6’, 2”, 
6”), 7.40 (7H, m, 7H, Ar-H 3’, 4’, 5’, 3”, 4”, 5”), 6.66 (1H, dd, J = 8.1, 0.95 Hz, 6H), 6.57 
(1H, d, J = 8.5, 0.95 Hz, 8H); 
13C NMR (CDCl3, 75.5 MHz): = 165.6, 161.5, 156.0, 139.1, 138.1, 129.5, 128.7, 126.5, 
111.2, 107.6, 107.5, 100.9.  
 
Triflate 264110 
 
 
 
 
In a 250 mL round bottom flask bezodioxinone 263 (8.8 g, 27.64 mmol, 1 equiv) 
was dissolved in CH2Cl2 (130 mL) at room temperature and pyridine (11.23 mL, 138.3 
mmol, 5 equiv) was added to the reaction mixture via syringe. The flask was cooled to -30 
oC under a nitrogen atmosphere, and trifluoromethanesufonic anhydride (6.05 mL, 35.97 
mmol, 1.3 equiv) was added dropwise to the reaction mixture. The mixture was stirred in 
the cold for 10 minutes and for 2 h at room temperature, then quenched with saturated 
NaHCO3 and extracted into EtOAc. The organic extracts were successively washed with 
water, saturated CuSO4 solution, water and brine, dried with MgSO4 and the solvent was 
evaporated to give the crude triflate 264 (11.94 g, 96%) as a yellow powder. Generally, the 
product is very clean and does not require any further purification.     
The 1H NMR and 13C NMR spectra of 264 were identical with those reported in the 
literature.110                                     
TLC: Rf (50% CH2Cl2/hexane) 0.62;  
IR υmax: 3075, 1750, 1620, 1579, 1472, 1428, 1288, 1206, 837, 749, 699 cm-1;  
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1H NMR (CDCl3, 300 MHz): δ = 7.57 (5H, m, 7H, Ar-H 2’, 6’, 2”, 6”), 7.37 (6H, m, Ar-
H 3’, 4’, 5’, 3”, 4”, 5”), 7.24 (1H, dd, J = 8.5, 0.95 Hz, 6H), 6.95 (1H, d, J = 8.3 Hz, 8H);  
13C NMR (CDCl3, 75.5 MHz): δ = 157.8, 157.1, 148.7, 138.6, 136.6, 129.6, 128.6, 126.6, 
118.2, 117.1, 116.4, 109.4, 107.5.  
 
Alkene 26689 
 
 
 
 
To an oven dried, 250 mL Schlenk flask with Teflon stir bar, containing a solution 
of LiCl (2.24 g, 52.88 mmol, 3.5 equiv) and Pd(PPh3)4 (0.34 g, 0.3 mmol, 0.02 equiv) in 
dry DMF (100 mL) was added, under the nitrogen, a solution of triflate 264 (6.8 g, 15.11 
mmol, 1 equiv ) in DMF (20 mL) via cannula, and the reaction mixture was stirred at room 
temperature for 1.5 h. Allyltributyltin (6.95 mL, 22.6 mmol, 1.5 equiv) was added and the 
reaction mixture was heated at 80 oC with stirring for 20 h. The flask was cooled to 0 oC 
followed by the addition of 1.0 M KF solution and the reaction mixture stirred for 30 
minutes at the same temperature and then extracted with Et2O (3 x 50 mL). The organic 
layers were combined, washed with water and brine, dried over MgSO4 and concentrated 
in vacuo. Purification on silica gel (30% EtOAc/hexane) impregnated with 10% w/w of 
finely grounded KF afforded alkene 266 (3.82 g, 74%) as a white solid in a high state of 
purity.  
The 1H NMR and 13C NMR spectra of 266 were identical with those reported in the 
literature.89 
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TLC: Rf (30 % EtOAc/hexane) 0.81;  
IR υmax: 3072, 3031, 1738, 1605, 1581, 1476, 1445, 1304, 1288, 1267, 1203, 1100, 1064, 
988 cm-1; 
1H NMR (CDCl3, 300 MHz): δ = 7.56 (4H, m, Ar-H 2’, 6’, 2”, 6”), 7.35 (1H, t, J = 8.01 
Hz, 7H), 7.26 (6H, m, Ar-H 3’, 4’, 5’, 3”, 4”, 5”), 6.91 (1H, dd, J = 8.2, 1.1 Hz, 8H), 6.81 
(1H, br. d, J = 7.6 Hz, 6H), 5.87 (1H, ddt, J = 17.1, 10.1, 6.3 Hz, -CH=CH2), 4.88 (1H, 
ddt, J = 10.2, 1.5, 1.5 Hz, cis CH=CH2 ), 4.67 (1H, ddt, J = 17.1, 1.7.7 Hz, trans 
CH=CH2), 3.77 (2H, br. d, J = 6.3 Hz, Ar-CH2-CH=CH2); 
 13C NMR (CDCl3, 75.5 MHz): δ = 160.2, 157.5, 145.2, 139.7, 136.3, 135.5, 129.1, 128.5, 
126.6, 125.3, 115.9, 115.8, 113.6, 106.0, 38.1. 
 
2.      Synthesis of amine fragment 285 
 
(S)-2-Bromosuccinic acid 279111 
 
 
 
 
A 100 mL round bottomed flask fitted with a mechanical stirrer was charged with 
L-aspartic acid 278 (12 g, 89.82 mmol, 1 equiv) and KBr (37.41 g, 314.3 mol, 3.5 equiv). 
Then, H2SO4 (4N, 200 mL) was added in one portion and the resulting solution was cooled 
to -10 oC (with an ice/methanol cooling bath). To this mixture a solution of sodium nitrite 
(9.24 g, 134.73 mmol, 1.5 equiv) in H2O (20 mL) was continuously added over a period of 
40 minutes, under a nitrogen atmosphere. The reaction mixture was stirred for an 
additional 2 h at -10 oC and then extracted with Et2O (3 x 50 mL). The combined ether 
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layers were washed with brine and dried (MgSO4), filtered and concentrated under reduced 
pressure to yield the crude product 279 as a white solid (17.73 g, 84%).  
The 1H NMR and 13C NMR spectra of 279 were identical with those reported in the 
literature.111 
 
1H NMR ((CD3)2CO, 300 MHz): δ = 11.40 (1H, br, s, 1C-OH), 4.64 (1H, dd, J = 8.6, 6.2 
Hz, 2H), 3.78 (1H, br, s, 4C-OH), 3.25 (1H, dd, J = 17.2, 8.6, 3H), 3.02 (1H, dd, J = 17.2, 
6.1, 3H); 
 13C NMR ((CD3)2CO, 75.5 MHz): δ = 171.1, 170.4, 40.1, 39.8 
 
Bromodiol 280111 
 
 
 
 
Employing flame-dried glassware under a nitrogen atmosphere, (S)-2-
bromosuccinic acid 279 (16 g, 81.2 mmol, 1 equiv) was dissolved in freshly distilled THF 
(100 mL) and the mixture cooled to -20 oC. Borane dimethylsulfide complex (21.6 mL, 
243.6 mmol, 2.0 M solution in THF, 3 equiv) was added via cannula and the reaction 
mixture was allowed to warm slowly to room temperature when a slightly exothermic 
reaction commenced. The mixture was stirred and maintained under a sweep of nitrogen 
gas for 16 h then quenched by dropwise addition of THF/H2O (20 mL, 1:1). K2CO3 (40 g) 
was added and a white solid appeared within several minutes, which was removed by 
decantation and washed with Et2O (2 x 50 mL). The organic phases were concentrated to 
an oily residue, which was then triturated with Et2O (3 x 50 mL) and borate salts removed 
by filtration. The ether extracts were combined, dried over MgSO4, filtered and then 
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concentrated. The residue (yellow oil) was purified by flash column chromatography to 
afford the desired product as an oil (12.07 g, 86 %). 
The 1H NMR and 13C NMR spectra of 280 were identical with those reported in the 
literature.111 
 
1H NMR (CDCl3, 300 MHz): δ =4.32 (1H, m), 3.85 (4H, m), 2.88 (2H, br, s), 2.12 (2H,m);  
13C NMR (CDCl3, 75.5 MHz): δ = 67.1, 60.0, 55.0, 37.7 
 
Methoxybenzyl bromide (B)  
 
 
 
 
To a flask containing 4-methoxybenzyl alcohol A (14 g, 173 mmol, 1 equiv) was 
added a solution of HBr (15 mL 48%), and the mixture was vigorously stirred at room 
temperature for 1 hour. The resulting mixture was diluted with Et2O (40 mL) and the 
organic layer was successively washed with saturated NHCO3, water, saturated aqueous 
NaCl, dried over K2CO3, filtered and concentrated to give unstable 4-methoxybenzyl 
bromide B  (19.46 g, 96 %) as a colorless oil. The crude product was found to be of 
sufficient purity for use in the next step without need for further purification. 
The 1H NMR and 13C NMR spectra of 263 were identical with those reported in the 
literature.111 
 
1H NMR (CDCl3, 300 MHz): δ = 7.35 (2H, d, J = 8.7 Hz, o-Ph-H), 6.89 (2H, J = 8.7, Hz, 
m-Ph-H), 4.53 (2 H, s, Br-CH2-Ph-), 3.82 (3H, s, Ph-O-CH3); 
13C NMR (CDCl3, 75.5 MHz): δ = 159.7, 130.4, 129.9, 114.2, 55.3, 34.0. 
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Epoxide 281111 
 
 
 
 
Under an atmosphere of nitrogen, sodium hydride (60% in mineral oil, 6.66 g, 
166.67 mmol, 3.5 equiv) was suspended in dry THF (75 mL) after being washed with 
hexane. The suspension was cooled to –10 oC and (S)-2-bromo-1,4-butanediol 280 (8 g, 
47.62 mmol, 1 equiv) in dry THF (20 mL) was added via cannula. After 1.5 h of stirring at 
–10 oC a solution of 4-methoxybenzyl bromide B (14.28 g, 71.43 mmol, 1.5 equiv) in THF 
(50 mL) was added followed by a solution of TBAI (1.75 g, 4.76 mmol, 0.1 equiv) in THF 
(10 mL). The white suspension was stirred for further 15 minutes at the same temperature 
and then allowed to warm to room temperature over 5 h (cooling bath slowly warmed to 
rt). The reaction was quenched by addition of saturated NH4Cl solution (50 mL), stirring 
was continued for 15 min, and the phases were separated. The aqueous layer was extracted 
with EtOAc (3 x 40 mL) and the combined organic extracts were washed with H2O, brine 
and dried with Na2SO4. After filtration and evaporation of the solvent, the crude product 
was purified by flash chromatography (50 % EtOAc /hexane) to provide the pure product 
281 (6.93 g, 64 %) as a colorless oil. 
The 1H NMR and 13C NMR spectra of 263 were identical with those reported in the 
literature.111 
 
TLC: Rf  = (50 % EtOAc/hexane) 0.58; 
IR υmax: 2997, 2926, 2859, 2838, 1736, 1612, 1585, 1512, 1464, 1361, 1301, 1244, 1173, 
1088, 1032, 907, 819 cm-1; 
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1H NMR (CDCl3, 300 MHz): δ = 7.27 (2H, d, J = 8.6 Hz, o-Ph-H), 6.89 (2H, d, J = 8.6 
Hz, m-Ph-H), 4.47 (2H, s, -O-CH2-Ph-), 3.81 (3H, s, -Ph-O-CH3), 3.61 (2H, m, 5H), 3.07 
(1H, m, 3H), 2.78 (1H, app. dd, J = 4.8, 0.7 Hz, 2H), 2.53 (1H, dd, J = 5.0, 2.7 Hz, 2H), 
1.84 (2H, m, 4H); 
13C NMR (CDCl3, 75.5 MHz): δ = 159.2, 130.3, 129.2, 113.8, 72.7, 66.7, 55.2, 50.0, 47.1, 
32.9. 
 
Alcohol 28250 
 
 
 
 
To a flame-dried two necked round bottom flask equipped with a magnetic stirring 
bar, a condenser and a rubber septum cap was added magnesium turnings (1.08 g, 45 
mmol, 1.5 equiv) and Et2O (20 mL). The suspension was stirred at room temperature for 
10 min, the solvent removed via syringe and Mg dried under a flame. Freshly distilled THF 
(23 mL, 2M with respect to Mg) was added to the flask and after 10 min a small crystal of 
I2 was added and stirred for another 10 min at room temperature when the mixture turned 
from yellow to turbid gray. 5-bromo-1-pentene (4.5 g, 30 mmol, 1 equiv) was added 
dropwise and the resulting solution was stirred at reflux temperature for 30 min. THF (30 
mL) was added to this solution of the Grignard reagent, and after cooling to -78oC a 
solution of Li2CuCl4  (0.1M in THF, 9.4 mL, 0.9 mmol, 0.03 equiv) was added dropwise 
via syringe. After the mixture was stirred for 25 min at the same temperature, a solution of 
281 (3.12 g, 15 mmol, 0.5 equiv) in THF (20 mL) was added dropwise. After the resulting 
mixture was stirred at - 78 oC for 15 min, it was allowed to warm to room temperature over 
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a period of 2 h. A saturated aqueous solution of NH4Cl (30 mL) was added and the 
reaction mixture was extracted with Et2O (3 x 50 mL). The organic layers were washed 
with water and brine, dried (Na2SO4) and the solvent removed by evaporation at reduced 
pressure. The residue was purified by flash chromatography (40 % EtOAc/hexane) to 
afford the desired product 282 (3.41 g, 78%) as a colorless oil.  
The 1H NMR and 13C NMR spectra of 263 were identical with those reported in the 
literature.50 
 
TLC: Rf = (40% EtOAc/hexane) 0.61; [𝛂]𝐃𝟐𝟔: - 9.13 (c 1.390, CH2Cl2); 
IR υmax: 3462, 2932, 2857, 1612, 1512, 1245, 1173, 1087, 1033, 910, 819 cm-1;  
1H NMR (CDCl3, 300 MHz): δ = 7.26 (2H, d, J = 8.5 Hz, o-Ph-H), 6.88 (2H, d, J = 8.6 
Hz, m-Ph-H), 5.82 (1H, ddt, J = 17.1, 10.2, 6.6 Hz, CH2=CH-), 5.01 (1H, ddt, J = 17.1, 
2.07, 1.5 Hz, trans CH=CH2), 4.94 (1H, ddt, J = 10.2, 1.1, 1.1 Hz, cis CH=CH2), 4.46 (2H, 
s, -O-CH2-Ph-), 3.81 (3H, s, -Ph-O-CH3), 3.66 (2H, m, -CH2-OPMB), 2.93 (1H, d, J = 3.0 
Hz, -OH), 2.06 (2H, q, J = 6.3 Hz, CH2=CH-CH2-), 1.73 (2H, m, -CH2-CH2-OPMB), 1.4 
(6H, m, CH2=CH-CH2-(CH2)3-CH-OH); 
 13C NMR (CDCl3, 75.5 MHz): δ = 159.2, 138.9, 130.0, 129.3, 114.3, 113.85, 72.9, 71.4, 
68.9, 55.2, 37.2, 36.3, 33.7, 28.9, 25.0. 
HRMS (ESI) calculated for C17H26O3 [M+H]+ 301.17742 found 301.17737. 
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Mesylate 283112 
 
 
 
To a cooled (0 °C) solution of alcohol 282 (2.4 g, 8.62 mmol, 1 equiv) in Et2O (60 
mL) was added triethylamine (4.23 mL, 30.17 mmol, 3.5 equiv) and methanesulfonyl 
chloride (2.33 mL, 30.17 mmol, 3.5 equiv). After 15 min of stirring at 0 oC the reaction 
mixture was warmed to room temperature and the reaction was left to proceed for further 
2h. Then the resulting mixture was quenched with water, the organic layer was separated 
and the aqueous solution was extracted with Et2O (3 × 50 mL). The combined organic 
extracts were washed successively with 50 mL H2O and 50 mL saturated aqueous NaCl, 
dried over Na2SO4 and concentrated affording the crude mesylate  (2.88 g, 94%) directly 
used for the  next step without further purification. 
 
TLC: Rf = (40% EtOAc/hexane) 0.56;  
1H NMR (CDCl3, 300 MHz): δ = 7.26 (2H, d, J = 8.6 Hz, o-Ph-H), 6.88 (2H, d, J = 8.6 
Hz, m-Ph-H), 5.81 (1H, ddt, J = 17.1, 10.2, 6.6 Hz, -CH=CH2), 5.01 (1H, ddt, J = 17.1, 
1.9, 1.6 Hz, trans CH=CH2), 4.95 (1H, ddt, J = 10.3, 1.3, 1.1, Hz, cis CH=CH2), 4.90 (1H, 
q, J = 6.16 Hz, -SO2(CH3)-O-CH), 4.46 (2H, ABq, J = 11.3 Hz, -O-CH2-Ph), 3.80 (3H, s, -
Ph-O-CH3), 3.56 (2H, m, -CH2-OPMB), 2.95 (3H, s, -SO2-CH3), 2.06 (2H, m, CH2=CH-
CH2-), 1.98 (2H, q, J = 6.1 Hz, MsO-CH-CH2-OPMB), 1.74 (2H, m, CH2=CH-(CH2)3-
CH2-), 1.41 (4H, m, CH2=CH-CH2-(CH2)2-);  
13C NMR (CDCl3, 75.5 MHz): δ = 159.2, 138.5, 130.1, 129.4, 114.6, 113.8, 81.2, 72.7, 
65.5, 55.2, 38.3, 34.8, 34.5, 33.4, 26.5, 24.1. 
HRMS (ESI) calculated for C18H28O2SNa [M+Na] + 379.15497 found 379.15494. 
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Azide 284113 
 
 
 
 
To a solution of mesylate 283 (2.80 g, 7.86 mmol, 1 equiv) in DMF (30 mL) was 
added NaN3 (1.12 g, 17.29 mmol, 2.2 equiv) and the mixture was stirred at reflux 
temperature (oil bath 72 °C) for 20 h. After cooling to room temperature the reaction 
mixture was quenched with water and extracted with diethyl ether (3 x 50 mL). The 
combined organic extracts were washed with water and brine and the organic layer was 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product, which was 
purified by silica gel column chromatography (10% Et2O/hexane) to give 284 (2.14 g, 
90%) as a colorless oil.  
 [𝛂]𝐃𝟐𝟔: - 27.78 (c 1.115, CH2Cl2);  
TLC: Rf = (10% Et2O/hexane) 0.58; 
IR υmax: 2933, 2858, 2096, 1612, 1512, 1245, 1089, 1034, 910, 819 cm-1; 
1H NMR (CDCl3, 300 MHz): δ = 7.30 (2H, d, J = 8.5 Hz, o-Ph-H), 6.92 (2H, d, J = 8.6 
Hz, m-Ph-H), 5.84 (1H, ddt, J = 17.1, 10.2, 6.6 Hz, -CH=CH2), 5.03 (2H, m, CH=CH2), 
4.48 (2H, ABq, J = 11.6 Hz, -O-CH2-Ph), 3.83 (3H, s, -Ph-O-CH3), 3.59 (2H, m, -CH2-
OPMB), 3.54 (1H, m, N3-CH-) 2.10 (2H, m, CH2=CH-CH2-), 1.79 (2H, m, N3-CH-CH2-
CH2-OPMB) 1.50 (6H, m, CH2=CH-CH2-(CH2)3-); 
13C NMR (CDCl3, 75.5 MHz): δ = 159.2, 138.6, 130.3, 129.3, 114.6, 113.8, 72.8, 66.5,  
60.1, 55.2, 34.7, 34.5, 33.6, 28.6, 25.5; 
HRMS (ESI) calculated for C17H25N3O2Na [M+Na]+ 326.18390, found 326.18396. 
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Amine 285114 
 
 
 
To a solution of azide 284 (4.8 g, 15.83 mmol, 1 equiv) and triphenylphosphine 
(16.86 g, 63.32 mmol, 4 equiv) in THF (100 mL) was added water (3.13 mL, 174.13 
mmol, 11 equiv) and the mixture was stirred for 3 h at 70 oC. The reaction mixture was 
cooled to room temperature and extracted with 0.5% solution of HCl. The aqueous phase 
was successively washed with Et2O (3 x 40 mL) and 5% aq. NaOH and then extracted with 
CH2Cl2 (3 x 40 mL). The combined organic extracts were dried over MgSO4, filtered and 
then concentrated under reduced pressure to give amine 285 (4.08 g, 65%) as an oil in a 
high state of purity. 
 [𝛂]𝐃𝟐𝟔: + 3.13  (c 1.280, CH2Cl2);  
TLC: Rf  (10% MeOH/CH2Cl2) 0.55; 
IR υmax: 3369, 2927, 2854, 1612, 1586, 1512, 1245, 1092, 1034, 908, 819, 721 cm-1; 
1H NMR (CDCl3, 300 MHz): δ = 7.25 (2H, d, J = 8.6 Hz, o-Ph-H), 6.86 (2H, d, 8.6 Hz, m-
Ph-H), 5.79 (1H, ddt, J = 17.1, 10.2, 6.6 Hz, -CH=CH2), 4.99 (1H, ddt, J = 17.1, 1.9, 1.6 
Hz, trans CH=CH2), 4.92 (1H, ddt, J = 10.2, 1.1, 1.1 Hz, cis CH=CH2), 4.42 (2H, br, s, -
O-CH2-Ph-), 3.78 (3H, s, -Ph-O-CH3), 3.54(2H, m, -CH2-OPMB), 2.86(1H, m, NH2-CH-), 
2.04 (2H, m, CH2=CH-CH2-), 1.79 (2H, m, NH2-CH-CH2-CH2-OPMB), 1.50 (2H, m, 
CH2=CH-(CH2)3-CH2-), 1.38 (4H, m, CH2=CH-CH2-(CH2)2-); 
13C NMR (CDCl3, 75.5 MHz): δ = 159.1, 138.9, 130.5, 129.2, 114.3, 113.7, 72.6, 67.8, 
55.2, 49.1, 38.2, 37.7, 33.7, 28.9, 25.5; 
HRMS (ESI) calculated for C17H28NO2 [M+H]+ 278.21146, found 278.21155. 
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3.      Synthesis of core of salicylhalamide 301 
 
Preparation of amide 28698 
 
 
 
 
 
To an oven-dried quartz test tube was added amine 285 (116.4 mg, 0.42 mmol, 1 
equiv.) and benzodioxinone 266 (215.5 mg, 0.63 mmol, 1.5 equiv.). The tube was then 
sealed with a rubber septum and after three vacuum/N2 cycles to remove air from the 
reaction tube, dry CH2Cl2 (10 mL) was added via syringe. After stirring for 5 min at room 
temperature, the reaction mixture was placed in a Rayonet photochemical reactor equipped 
with 8 x 300 nm lamps and the degassed solution was irradiated for 6 h. The solvent was 
evaporated under reduced pressure and the crude product was purified by column 
chromatography affording 286 (151.4 mg, 55%) as a colorless oil. 
 [𝛂]𝐃𝟐𝟑: -1.6 (c 0.790, CH2Cl2); 
TLC: Rf (30% EtOAc/hexane) 0.55; 
IR υmax: 3280, 3240, 2932, 2857, 1631, 1517, 1462, 1245, 1091, 909, 817, 761 cm-1; 
1H NMR (CDCl3, 300 MHz): δ = 10.65 (1H, s, Ph-OH), 7.25 (1H, t, J = 7.9 Hz, H5), 7.19 
(2H, d, J = 8.6 Hz, o-Ph-H), 6.87 (1H, dd, J = 1.1, 8.2 Hz, H6), 6.81 (2H, d, J = 8.6 Hz, m-
Ph-H), 6.66 (1H, dd, J = 7.5, 1.1 Hz, H4), 6.61 (1H, d, J = 8.5 Hz, -NH), 6.05 (1H, ddt J = 
17.2, 10.2, 5.1 Hz, H9), 5.79 (1H, ddt, J = 17.1, 10.2, 6.6 Hz, H12), 5.20 (1H, ddt, J = 
10.2, 1.7, 1.7 Hz, cis H10), 5.02 (1H, ddt, J = 17.2, 1.9, 1.6 Hz trans H11), 4.94 (1H, ddt, 
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J = 10.1, 1.2, 0.9 Hz, cis H11), 4.90 (1H, ddt, J = 17.3, 1.8, 1.5 Hz trans H10), 4.40 (2H, s, 
H20), 4.28 (1H, m, H17), 3.78 (3H, s, H23), 3.55 (2H, m, H19), 3.43 (2H, m, H8), 2.05 
(2H, dt, J = 6.9, 6.9 Hz, H13), 1.93 (1H, m, H18), 1.72 (1H, m, H18), 1.54 (2H, m, H16), 
1.39 (4H, m, H14, H15);  
13C NMR (CDCl3, 75.5 MHz): δ = 169.2, 159.3, 159.2, 138.6, 138.1, 136.4, 131.8, 130.0, 
129.4, 122.6, 118.8, 117.6, 115.8, 114.5, 113.7, 72.9, 67.0, 55.2, 48.3, 38.4, 34.4, 34.2, 
33.5, 28.6, 25.4; 
 HRMS (ESI) calculated for C27H35NO4Na [M+Na]+ 460.24583, found 460.24586. 
 
Acetyl protected phenol 290115 
 
 
 
 
 
To a solution of 286 (0.909 g, 2.07 mmol, 1.00 equiv) and 4-(dimethylamino) 
pyridine (DMAP, 378 mg, 1.5 equiv) in CH2Cl2 (10 mL) was added pyridine (0.84 mL, 
10.3 mmol, 5 equiv) and freshly distilled acetic anhydride (0.29 mL, 3 mmol, 1.5 equiv). 
After stirring for 12 h at room temperature, the mixture was diluted with Et2O (20 mL), 
quenched with aqueous NaHCO3 (40 mL) and stirred at ambient temperature for 10 min. 
The organic layer was separated and the aqueous layer was extracted with Et2O (3x40 mL). 
The combined organic layers were washed successively with CuSO4 solution, water, 
NaHCO3 solution and saturated aqueous NaCl, dried over Na2SO4 and evaporated. The 
residue was purified by flash chromatography (3%, EtOAc/ CH2Cl2) to give 290 as a white 
solid (915 mg, 90%) suitable for X-ray crystallographic analysis.  
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mp 55 oC;  
TLC: Rf (3%, EtOAc/ CH2Cl2) 0.91;  
Rf (40%, EtOAc/ CH2Cl2) 0.52; [𝛂]𝐃𝟐𝟑: +2.4 (c 0.910, CH2Cl2); 
IR υmax: 3296, 3074, 2933, 2858, 1764, 1641, 1610, 1512, 1456, 1246, 1198, 1092, 1018, 
911, 820, 733 cm-1; 
1H NMR (CDCl3, 300 MHz): δ = 7.33 (1H, t, J = 7.9 Hz, H5), 7.19 (2H, d, J = 8.6 Hz, o-
Ph-H), 7.12 (1H, d, J = 7.6 Hz, H6), 6.95 (1H, d, J = 8.1 Hz, H4), 6.82 (2H, d, J = 8.6 Hz, 
m-Ph-H), 6.07 (1H, d, J = 8.8 Hz, -NH), 5.93 (1H, ddt, J = 17.0, 10.2, 6.5 Hz, H9), 5.80 
(1H, ddt, J = 17.1, 10.2, 6.6, Hz, H12), 5.07 (1H, ddt, J = 10.2, 1.5, 1.3 Hz, cis H10), 4.95 
(1H, ddt, J = 17.0, 1.7, 1.5 Hz trans H11), 5.00 (1H, ddt, J = 17.0, 1.9, 1.5 Hz, trans H10), 
4.94 (1H, ddt, J = 10.0, 1.9, 1.1 Hz,  cis H11), 4.41 (2H, ABq, J = 11.5 Hz, H20), 4.23 
(1H, m, H17), 3.79 (3H, s, H23), 3.56 (2H, m, H19), 3.33 (2H, d, J = 6.4 Hz, H8), 2.27 
(3H, s, -O-CO-CH3), 2.05 (2H, m, H13), 1.82 (1H, m, H18), 1.64 (1H, m, H18), 1.43 (2H, 
m, H16), 1.32 (4H, m, H14, H15);  
13C NMR (CDCl3, 75.5 MHz): δ = 170.0, 165.5, 159.1, 147.0, 138.8, 138.6, 136.6, 131.0, 
130.1, 129.6, 129.3, 127.3, 120.5, 116.5, 114.5, 113.7, 72.8, 66.8, 55.2, 47.7, 37.0, 34.2, 
34.0, 33.6, 28.8, 25.4, 21.0; 
 HRMS (ESI) calculated for C29H37NO5Na [M+Na]+ 502.25639, found 502.25646. 
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A 100 mL, flame-dried, round bottomed flask equipped with a reflux condenser 
and a magnetic stirring bar, was charged with 290 (390 mg, 0.814 mmol, 10 equiv) before 
being sealed with a rubber septum and evacuated and backfilled with N2 three times. 
Freshly distilled CH2Cl2 was introduced and the resulting solution was stirred at room 
temperature for 2 min. A solution of Grubbs 1st - generation catalyst (Cy3P)2Cl2Ru=CHPh 
(66.9 mg, 0.081 mmol, 1 equiv) in degassed CH2Cl2 (8 mL) was added dropwise and the 
reaction mixture was heated to reflux for 24 h. The cooled (room temperature) solution 
was evaporated until ca. 30mL remained and then filtered through a short plug of silica gel 
eluting with EtOAc. After the filtered solution was stirred with activated charcoal (20g, 50 
equiv wt of crude product) for 12 h at room temperature, the carbon was removed by 
filtration. The removal of solvent in vacuo and purification on a silica gel chromatographic 
column (EtOAc/hexane 1:20 → 1:4 → 1:1) afforded the (E)-macrolactam 293 (257.76 mg, 
66%) and (Z)-macrolactam 296 (41.2 mg, 10%) as white solids. 
 
(E)-macrolactam 293 
 mp 117 oC; 
TLC: Rf (50% EtOAc/hexane) 0.44; [𝛂]𝐃𝟐𝟑: -98.3 (c 0.720, CH2Cl2); 
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IR υmax: 3293, 2926, 2855, 1765, 1644, 1512, 1455, 1246, 1200, 1089, 1020, 804, 733 cm-
1; 1H NMR (CDCl3, 300 MHz): δ = 7.30 (1H, t, J = 7.8 Hz, H5), 7.26 (2H, d, J = 8.6 Hz, 
o-Ph-H), 7.11 (1H, d, J = 7.5 Hz, H6), 6.92 (1H, d, J = 8.1 Hz, H4), 6.88 (2H, d, J = 8.6 
Hz, m-Ph-H), 5.51 (1H, d, J = 8.6 Hz, -NH), 5.50 (1H, m, trans H9), 5.26 (1H, dddd, J = 
14.9, 10.3, 3.3, 1.3 Hz, trans H10), 4.46 (2H, ABq, J = 11.6 Hz, H18), 4.11 (1H, m, H15), 
3.92 (1H, dd, 14.2, 3.8 Hz, H8), 3.73 (3H, s, H23), 3.58 (2H, app. t, J = 7.3 Hz, H17), 3.21 
(1H, dd, J = 14.2, 2.5 Hz, H8), 2.16 (3H, s, 3C-O-CO-CH3), 1.72 (4H, m, H16, H14), 1.41 
(4H, m, H11, H13), 1.11 (2H, m, H12);  
13C NMR (CDCl3, 75.5 MHz): δ = 170.7, 165.3, 159.1, 147.3, 140.6, 133.1, 130.7, 130.4, 
129.9, 129.4, 128.5, 128.0, 120.8, 113.8, 72.8, 67.3, 55.2, 45.0, 37.9, 36.7, 32.7, 32.6, 24.7, 
20.9, 20.7; 
HRMS (ESI) calculated for C27H33NO5Na [M+Na]+ 474.22509, found 474.22504. 
 
(Z)-macrolactam 296 
mp 119-120 oC 
TLC: Rf (50% EtOAc/hexane) 0.43; [𝛂]𝐃𝟐𝟕: - 8.82 (c 0.720, CH2Cl2); 
IR υmax: 3289, 2928, 2855, 1764, 1642, 1512, 1455, 1245, 1200, 1094, 1023, 818,733cm-1; 
1H NMR (CDCl3, 300 MHz): δ = 7.35(1H, t, J = 7.8 Hz, H5), 7.24 (2H, d, J = 8.6 Hz, o-
Ph-H), 7.20 (1H, d, J = 7.8 Hz, H6), 6.93 (1H, d, J = 8.1 Hz, H4), 6.87 (2H, d, J = 8.5 Hz, 
m-Ph-H), 5.80 (1H, d, J = 8.1 Hz, -NH), 5.46 (1H, app. t, J = 10.3 Hz, cis H9), 5.18 (1H, 
app. t, J = 10.3 Hz, cis H10), 4.44 (2H, ABq, J = 11.9 Hz, H18), 4.28 (1H, m, H15), 3.81 
(3H, s, H23), 3.70 (1H, dd, J = 14.9, 4.8 Hz, H8), 3.52 (2H, m, H17), 3.22 (1H, br d, J = 
14.9 Hz, H8), 2.18 (3H, s, 3C-O-CO-CH3), 1.94 (2H, m, H16), 1.73 (2H, m, H14), 1.42 
(2H, m, H11, H13), 1.02 (2H, m, H12); 
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13C NMR (CDCl3, 75.5 MHz): δ = 170.4, 166.1, 159.5, 147.1, 140.6, 131.3, 130.7, 130.5, 
130.3, 130.2, 129.5, 128.1, 120.5, 114.1, 73.0, 67.4, 55.6, 47.6, 33.1, 31.8, 30.3, 26.6, 24.5, 
21.2, 19.0;  
HRMS (ESI) calculated for C27H33NO5Na [M+Na]+ 474.22509, found 474.22504. 
 
Primary alcohol 297116 
 
 
  
 
 
To a solution of PMB ether 293 (0.120 mg, 0.266 mmol, 1 equiv) in CH2Cl2 (40 
mL) at 0 °C was added pH 7 buffer (6 mL) followed by DDQ (301.91 mg, 1.33 mmol, 5 
equiv). After being stirred at 0 °C for 5 min and at room temperature for 2 h, the reaction 
was quenched with saturate aqueous NaHCO3 and saturated aqueous Na2S2O3, and 
extracted with CH2Cl2 (3x20 mL). The combined organic extracts were washed with brine, 
dried over MgSO4, filtered and then concentrated under reduced pressure. The residue was 
purified by flash chromatography to afford 297 (81 mg, 84%) as a white solid.  
mp 156-157 oC; 
TLC: Rf (40% EtOAc/hexane) 0.47; [𝛂]𝐃𝟐𝟑: -169.5 (c 0.710, CH2Cl2); 
IR υmax : 3369, 3264, 2944, 2926, 2862, 1759, 1548, 1456, 1215, 966, 750 cm-1; 
1H NMR (CDCl3, 300 MHz): δ = 7.33 (1H, t, J = 7.9 Hz, H5), 7.13 (1H, d, J = 7.5 Hz, 
H6), 6.94 (1H, d, J = 8.2, H4), 5.47 (1H, d, J = 8.7 Hz, NH), 5.48 (1H, m, H10), 5.27 (1H, 
m, H9), 4.15 (1H, m, H15), 3.89 (1H, dd, J = 14.0, 3.3 Hz, H8), 3.72 (2H, m, H17), 3.20 
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(1H, app. dd, J = 14.0, 2.3 Hz, H8), 2.26 (3H, s, 3C-O-CO-CH3), 1.81 (2H, m, H16), 1.61 
(2H, m, H14), 1.48 (2H, m, H11), 1.33 (2H, m, H13), 1.13 (2H, m, H12);  
13C NMR (CDCl3, 75.5 MHz): δ = 170.9, 167.6, 147.2, 140.4, 133.3, 130.3, 130.1, 128.6, 
128.1, 120.9, 58.3, 43.6, 40.0, 37.9, 33.8, 32.5, 24.4, 20.9, 20.8;  
HRMS (ESI) calculated for C19H25NO4Na [M+Na]+ 354.16758, found 354.16763.  
 
Synthesis of Aldehyde 298117 
 
 
 
 
 
Dess-Martin periodinane (1.53 g, 3.625 mmol, 4 equiv) was added in one portion to a 
cooled (0 oC) solution of alcohol 297 (300 mg, 0.906 mmol, 1.00 equiv) in CH2Cl2 (50 mL) 
and the resultant mixture was stirred for 45 min at 25 oC. The white suspension was then 
cooled to 0 oC and aqueous solution of Na2S2O3 (20%, 100 mL) and saturated aqueous 
solution of NaHCO3 (100 mL) were added and the resulting mixture stirred for 30 minutes 
until it became clear.  The mixture was diluted with CH2Cl2 (50 mL), the organic layer was 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined 
organic extracts were washed with a 40% aqueous solution of sodium thiosulfate (200mL) 
and brine, dried over MgSO4 and concentrated. Flash chromatography provided 298 
(250.47 mg, 90%) as a white solid, which was recrystallized from EtOAc affording 
colorless crystals suitable for X-ray crystallographic analysis.  
mp 168 oC; 
TLC: Rf (80% EtOAc/hexane) 0.78; 
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[𝛂]𝐃𝟐𝟑: -112.5 (c 1.030, CH2Cl2);  
IR υmax: 3254, 2930, 2852, 2737, 1763, 1724, 1634, 1546, 1458, 1202, 1019, 973, 756 cm-
1; 1H NMR (CDCl3, 300 MHz): δ = 9.81 (1H, t, J = 2.1 Hz, H17), 7.28 (1H, t, J = 7.8 Hz, 
H5), 7.08 (1H d, J = 7.4 Hz, H6), 6.90 (1H, d, J = 8.1 Hz, H4), 5.74 (1H, d, J = 7.8 Hz, 
NH), 5.47 (1H, dddd, J = 14.9, 10.1, 4.5, 1.6 Hz, H10), 5.26 (1H, dddd, J = 14.9, 10.1, 3.4, 
1.3 Hz, H9), 4.44 (1H, m, H15), 3.82 (1H, dd, J = 14.1, 3.9 Hz, H8), 3.21 (1H, dq, J = 
14.1, 2.7 Hz, H8), 2.57, (2H, m, H16), 2.29 (3H, s, 3C-O-CO-CH3), 2.18 (1H, m, H14), 
1.69 (1H, m, H14), 1.56 (2H, m, H11), 1.43 (2H, m H13), 1.11 (2H, m, H12);  
13C NMR (CDCl3, 75.5 MHz): δ = 200.4, 171.0, 165.7, 147.3, 140.4, 132.7, 130.2, 130.1, 
128.49, 128.44, 120.9, 50.2, 43.0, 37.9, 32.9, 32.7, 24.6, 21.0, 20.8; 
HRMS (ESI) calculated for C19H23NO4Na [M+Na]+ 352.15193, found 352.15199. 
 
Vinyl iodide 29999 
 
 
 
 
 
Chromium chloride (II) (112.95 mg, 0.919 mmol, 7 equiv) was added to a dry 50 
mL round bottomed flask and was flame dried at reduced pressure for 5 min. After cooling 
to rom temperature under a nitrogen atmosphere, dry THF (5 mL) was added and the slurry 
solution was stirred for 30 min at the same temperature followed by 5 min at 0 °C. A 
nitrogen purged solution of aldehyde 298 (43.20 mg, 0.131 mmol, 1.00 equiv) and 
iodoform (155.09 mg, 0.394 mmol, 3 equiv) in dry THF (4 mL) was then added via 
cannula and the initial grey suspension turned almost immediately reddish-brown. After 
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being stirred at room temperature for 8 h, the reaction mixture was diluted with water and 
extracted in Et2O. The aqueous phase was extracted with Et2O (3 x 20 mL) and the 
combined organic layers were washed with aqueous solution of Na2S2O3, brine, dried over 
Na2SO4, filtered and concentrated in vacuo. The product was purified by chromatography 
(30% EtOAc/hexane) affording the (E)-iodoalkene 299 (38.06 mg, 72%) as a white solid 
and a small amount of Z-isomer 299 A. 
  
(E)-iodoalkene 299 
mp 154-156 oC; 
 TLC: Rf (80% Et2O/hexane) 0.72; [𝛂]𝐃𝟐𝟑: -96.4o (c 0.805, CH2Cl2); 
IR υmax: 3255, 2924, 1760, 1633, 1546, 1456, 1207, 1019, 966, 873, 708 cm-1; 
1H NMR (CDCl3, 300 MHz): δ = 7.32 (1H, t, J = 7.9 Hz, H5), 7.16 (1H, d, J = 7.6 Hz, 
H6), 6.91 (1H, dd, J = 8.08, 0.93 Hz, H4), 6.37 (1H, dtd, J = 14.3, 7.3, 7.1 Hz, H17), 6.09 
(1H, app. dt, J = 14.3, 1.2 Hz, H18), 5.92 (1H, d, J = 8.1 Hz, NH), 5.42 (1H, app. t, J = 
10.0 Hz, H9), 5.13 (1H, app. t, J = 10.5 Hz, H10), 4.10 (1H, m, H15), 3.61 (1H, dd, 15.1, 
4.7 Hz, H8), 3.17 (1H, br dd, J = 14.9, 2.5 Hz, H8), 2.38 (1H, m, H11), 2.29 (3H, m, 3C-
O-CO-CH3), 2.17 (2H, m, H16), 1.94 (1H, m, H11), 1.83 (1H, m, H13), 1.48 (1H, m, 
H13), 1.37 (2H, m, H14), 1.16 (2H, m, H12); 
13C NMR (CDCl3, 75.5 MHz): δ = 170.14, 166.0, 146.8, 142.3, 140.1, 130.7, 130.5, 130.0, 
129.9, 127.6, 120.2, 77.5, 49.0, 39.2, 31.4, 30.1, 26.2, 24.2, 21.4, 18.5; 
HRMS (ESI) calculated for C20H24INO3Na [M+Na]+ 476.06931, found 476.06950. 
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A 10 mL, flame-dried, round bottomed flask equipped with a magnetic stirring bar, 
was charged with iodoalkene 299 (34.2 mg, 0.075 mmol, 1.00 equiv), Cs2CO3 (132.3 mg, 
0.375 mmol, 5 equiv), CuI (28.75 mg, 0.151 mmol, 2 equiv), N, N’-ethylenediamine 
(40.96 µL, 0.375 mmol, 5 equiv) and dienamide 101 (49 mg, 0.375 mmol, 5 equiv) before 
being sealed with a rubber septum and evacuated and backfilled with N2 three times. To a 
separate dried flask was added dry DMF (2 mL), degassed rigorously (3 x) by the freeze-
pump-thaw technique and transferred via cannula to the first flask. The mixture was stirred 
under nitrogen at room temperature and monitored by TLC. After 2 h, the reaction mixture 
was diluted with water, the organic layer was separated and the aqueous layer was 
extracted with EtOAc (3 x 15 mL). The combined organic extracts were washed with water 
and brine, dried over MgSO4 and concentrated. Flash chromatography provided 301 (19.7 
mg, 64%) as a white solid.  
mp 151-152 oC; 
TLC: Rf (55% EtOAc/hexane) 0.41; [𝛂]𝐃𝟐𝟑: -13.4o (c 0.210, CH2Cl2); 
IR υmax: 3348, 2931, 2471, 2243, 2214, 2141, 2071, 1633, 1595, 1461, 1121, 1090, 972, 
821 cm-1 
1H NMR (CD3OD, 300 MHz): δ = 7.32 (1H, dt, J = 10.8, 1.2 Hz, H22), 7.08 (1H, t, J = 
7.9 Hz, H5), 6.87 (1H, dd, J = 11.6, 1.1 Hz, H21), 6.80 (1H, d, J = 14.4 Hz, H18), 6.73 
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(1H, d, J = 7.9 Hz, H4), 6.6 (1H, d, J = 7.7 Hz, H6), 5.83 (1H, dddd, J = 10.8, 7.7, 7.5, 1.3, 
1.1 Hz, H23), 5.70 (1H, d, J = 11.6 Hz, H20), 5.41 (2H, m, H17, H10), 5.26 (1H, m, H9), 
3.97 (1H, m, H15), 3.76 (1H, dd, J = 14.3, 4.1 Hz, H8), 3.13 (1H, br dd, J = 14.3, 2.3 Hz, 
H8) 2.31 (2H, dquin, J = 7.5, 7.5, 7.5, 7.5, 1.5 Hz, H24), 2.25 (2H, m, H16), 2.16 (1H, m, 
H11), 1.69 (1H, m, H11), 1.56 (2H, m, H12), 1.42 (2H, m, H14), 1.20 (2H, m, H13), 1.03 
(3H, t, J = 7.5 Hz, H25); 
13C NMR (CD3OD, 75.5 MHz): δ = 170.0, 165.9, 155.9, 142.6, 141.0, 137.7, 133.4, 131.0, 
130.0, 126.3, 125.7, 125.5, 122.5, 120.6, 115.2, 112.1, 49.6, 39.3, 37.0, 33.9, 32.9, 26.3, 
22.2, 21.6, 14.5; 
HRMS (ESI) calculated for C25H32N2O3Na [M+Na]+ 431.23051, found 431.23053. 
 
4.     Synthesis of amide fragment 10165,67,94 
 
Synthesis of gem-dibromide 17767 
 
 
 
An oven dried 100 mL two-necked round-bottomed flask equipped with a stirrer 
and a calcium chloride drying tube is charged with 40 mL of CH2Cl2 and cooled at -5 0C. 
Carbon tetrabromide (2 g, 6.03 mmol, 1 equiv) was added in one portion and the solution 
was stirred in the cold for 25 minutes. To this solution was added freshly distilled 
propionaldehyde 176 (0.35 g, 6.03 mmol, 1 equiv) and PPh3 (3.95 g, 15.07 mmol, 2.5 
equiv) over 30 minutes. The mixture was stirred at the same temperature for 20 minutes, 
allowed to warm to room temperature and stirred for additional 2 hours. Upon 
H
O
CBr4 , Ph3P
CH2Cl2
-5oC to 25oC
68%
Br
Br
302 303 177176
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consumption of the starting material, 20 mL n-pentane was added, under stirring, when the 
reaction mixture thickened noticeably. The slurry was filtered and the solid was washed 
with n-pentane; the filtrates were combined and the solvent was removed under vacuum. 
The resulting liquid was distilled under reduced pressure to yield 177 (0.87 g, 68%) as a 
colorless liquid.  
The 1H NMR and 13C NMR spectra of 177 were identical with those reported in the 
literature. 
 
IR υmax: 2970, 2923, 1713, 1139, 805, 674 cm-1; 
1H NMR (CDCl3, 300 MHz): δ = 6.40 (1H, t, J = 7.19 Hz), 2.13 (1H, d, J = 7.4 Hz), 1.05 
(1H, t, J = 7.5 Hz); 
13C NMR (CDCl3, 75.5 MHz): δ = 140.1, 88.2, 26.5, 12.3. 
 
Z – iodoacrylate 16667 
  
 
 
 
To a stirred solution of LiI (10.12 g, 75.61 mmol, 1.5 equiv) in acetonitrile (74 mL) 
was added methyl propiolate 179 (4.23 g, 50.35 mmol, 1 equiv) and acetic acid (6 mL). 
After heating at 70 oC for 19 h, the reaction mixture was diluted with 200 mL of H2O and 
the mixture was extracted with diethyl ether (3 x 100 mL). The combined organic extracts 
were sequentially washed with a saturated aqueous solution of sodium thiosulfate and 
brine. The organic layer was dried over MgSO4, filtered and concentrated in vacuo to give 
the crude product, which was purified by silica gel column chromatography (20% 
Et2O/hexane) to give 166 (8.42 g, 79%) as a colorless oil.  
O
OCH3
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CH3CN, 70oC
79%
I OCH3
O
304 305 179 166 
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The 1H NMR and 13C NMR spectra of 166 were identical with those reported in the 
literature. 
 
TLC: Rf (20% Et2O/hexane) 0.67; 
IR υmax: 3031, 2950, 2840, 1724, 1596, 1324, 1200, 1161, 806 cm-1. 
1H NMR (CDCl3, 300 MHz): δ = 7.48 (1H, d, 8.9 Hz), 6.91 (1H, d, 8.9 Hz), 3.78 (3H, s); 
13C NMR (CDCl3, 75.5 MHz): δ = 164.9, 129.5, 95.3, 51.6. 
 
Preparation of enyne 17267 
 
 
 
 
Under a nitrogen atmosphere, to a solution of 1,1- dibromobutene 177 (2.78 g, 13 
mmol, 1 equiv) in dry THF (40 mL) at -78 oC was added dropwise n-BuLi (11.44 mL, 2.5 
M in hexane, 2.2 equiv), and the mixture was stirred at the same temperature for 1.5h and 
for 1h at room temperature. The reaction was then brought to -50oC and a solution of 
ZnCl2 (2.04 g, 15 mmol, 1.15 equiv) in THF (20 mL) was added via syringe. The reaction 
mixture was allowed to warm to ambient temperature. A solution of ester 305 (2.09 g, 9.86 
mmol, 0.76 equiv) in THF (20 mL) and Pd(PPh3)4 (232 mg, 0.20 mmol, 2 mol%) in THF 
(20 mL) were subsequently introduced, and stirring of the mixture was continued for 5h. 
The reaction was quenched with water followed by extraction of the aqueous layer with 
diethyl ether. The combined organic layers were washed with water and brine, dried with 
MgSO4, and filtered. The solvent was removed in vacuo to give crude product that was 
chromatographed on silica gel to provide 172 (1.19g, 88 %) as a colorless liquid.  
The 1H NMR and 13C NMR spectra of 172 were identical with those reported in the 
177 
172 
166, ZnCl2, THF 
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Experimental Chapter 3
literature. 
TLC: Rf  = 0.55 (5% EtOAc/hexane). 
IR υmax: 3012, 2979, 2950, 2915, 2880, 2210, 1726, 1609, 1436, 1404, 1290, 1232, 1192, 
1170, 814 cm-1. 
1H NMR (CDCl3, 300 MHz): δ = 6.14 (1H, dt, J = 11.3, 2. 3 Hz), 6.03 (1H, J =11.3 Hz), 
3.74 (3H, s), 2.45 (2H, qd, J = 7.5, 2.3 Hz), 1.21 (3H, t, J = 7.5); 
13C NMR (CDCl3, 75.5 MHz): δ = 165.3, 126.9, 124.2, 105.4, 77.0, 51.3, 13.7, 13.4.  
 
Synthesis of dienoate 16967 
 
 
 
 
In a two-neck flask was placed a solution of 172 (74.9 mg, 0.57 mmol, 1 equiv) in 
CH2Cl2 (36 mL, dried over calcium hydride). After three vacuum/H2 cycles to remove air 
from the reaction flask, Lindlar’s catalyst (3.176 mg, 4 wt %) and freshly distilled 
quinoline (4µL, 6 mol%) were added under positive H2 pressure. The resulting suspension 
was stirred and hydrogenated at balloon pressure and room temperature for 3h. The 
resulting mixture was filtered through Celite to remove the catalyst, washed with CH2Cl2 
(3x40mL) and the filtrated was concentrated in vacuo. The resulting crude product was 
purified by flash chromatography (5% Et2O/hexane). The diester 169 was obtained as a 
colorless liquid (51.67g, 68%).  
The 1H NMR and 13C NMR spectra of 169 were identical with those reported in the 
literature. 
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TLC: Rf (5% Et2O/hexane) 0.48; 
1H NMR (CDCl3, 300 MHz): δ = 7.16 (1 H, dd, J = 11.1, 1.1, Hz), 6.87 (1 H, J = 11.8, 1.0 
Hz), 5.89-5.78 (1H, m), 5.60 (1 H, d, J = 11.4 Hz), 3.65 (3H, s), 2.20 (2 H, dq, J = 7.5, 1.5 
Hz), 0.96 (3H, t, J = 7.5 Hz); 
13C NMR (CDCl3, 75.5 MHz): δ = 166.9, 143.2, 139.0, 123.7, 116.9, 77.4, 77.0, 76.6, 
51.1, 20.8, 13.9. 
 
(ZZ) - heptadienamide 10167 
 
 
 
 
A mixture of diene 172 (183 mg, 1.30 mmol, 1 equiv) and 28% solution of NH4OH 
(35 mL/mmol) at room temperature was stirred for 4 days. Cold water was added and after 
stirring for 15 minutes the mixture was extracted with ethyl acetate (3 x 40 mL). The 
combined organic extracts were washed successively with water and brine. Following 
drying over anhydrous MgSO4, the suspension was filtered, volatiles were removed under 
reduced pressure, and the residue was subjected to silica gel column chromatography 
(eluting with ethyl acetate) to afford 101 as a white solid (51.52 mg, 46%).  
The 1H NMR and 13C NMR spectra of 101 were identical with those reported in the 
literature. 
 
TLC: Rf  (EtOAc) 0.64; 
IR υmax: 3395, 3187, 3010, 2968, 2934, 1650, 1604, 1590, 1453, 1324, 806 cm-1; 
172 
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1H NMR (CDCl3, 300 MHz): δ = 7.13 (1H, m), 6.73 (dd, J =11,6, 1.1 Hz) , 6.11 – 5.88 (br 
s, 2H), 5.82 – 5.71 (1H, m), 5.59 (1 H, d, J = 11.5 Hz), 2.19 (2 H, dq, J = 7.5, 1.5 Hz), 0.9 
(3 H, t, J = 7.5 Hz). 
13C NMR (CDCl3, 75.5 MHz): δ = 168.8, 141.8, 136.1, 123.6, 119.4, 20.7, 13.9.  
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Appendix C
 
Table 6 
 
Synthesis of alcohol 
precursor 
Total steps Overall yield 
De Brabander46 10 57% 
Rizzacasa52 8 20% 
Fürstner48 11 44.7% 
Smith50 7 42.4% 
Labrecque47 9 12% 
Snider49 8 32% 
Maier51 13 14.4% 
Georg54 4 51.4% 
Hanson55,56 14 43.8% 
